Analysis method using in-sample calibration curves by multiple reaction isotope molecular species reaction monitoring
The ISCC-MIRM method addresses the challenge of using external calibration curves by quantifying analytes within the sample matrix, providing accurate and efficient analysis of biomarkers and drugs in preclinical and clinical trials.
Patent Information
- Application Number
- JP2021531713
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-12-04
- Filing Date
- 2019-12-03
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2039-12-03
AI Technical Summary
The intrinsic nature of biomarkers often precludes the use of external calibration curves with authentic reference standards, making it difficult and costly to analyze proteins using stably isotopically labeled analytes, which are required for accurate LC-MS/MS assays in preclinical and clinical trials.
The method involves constructing an in-sample calibration curve (ISCC) using multiple isotope species reaction monitoring (MIRM) of stable isotope-labeled analytes, eliminating the need for external calibration curves and reducing the total instrument time by quantifying analytes within the sample matrix.
This approach allows for accurate and efficient quantification of analytes, such as proteins and small molecules, by establishing a stable and accurate assay performance with reduced instrument time, particularly useful in clinical diagnostics and drug development.
Smart Images

Figure 0007584418000010 
Figure 0007584418000011 
Figure 0007584418000012
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 775,318, filed December 4, 2018. The entire contents of U.S. Provisional Application No. 62 / 775,318 are incorporated herein by reference.
[0002] References to sequence listings submitted electronically via EFS-WEB This application contains a Sequence Listing submitted electronically via EFS-Web (Name: "3338_148PC01_SL_ST25.txt"; Size: 844 bytes; and Creation Date: December 3, 2019), which is incorporated by reference in its entirety. [Background technology]
[0003] With the recent rapid development of discovery medicine research, quantitative determination of biomarkers in preclinical and clinical trials, and quantitative proteomics have increasingly important roles in molecular and cell biology research, drug discovery and development, such as identifying and validating potential biomarkers, enabling patient stratification and dose selection, serving as surrogate endpoints, and establishing PK / PD relationships at the site of action. It is well known that the use of external calibration curves prepared in the same biological matrix as the originating study samples, and the use of stably isotope-labeled (SIL) analytes in both the external calibration curves and originating study samples as internal standards for the assay, are important in the development of accurate and stable liquid chromatography-tandem mass spectrometry (LC-MS / MS) assays for the quantitative determination of small molecule drugs and biological drugs in biological matrices.
[0004] However, for biomarker measurements in preclinical and clinical trials, the intrinsic nature of the biomarker often precludes the use of external calibration with a true reference standard in a true matrix. Creating an external calibration with a SIL surrogate analyte in a true matrix is an alternative, and can provide similar assay performance to an assay with a true analyte in a true matrix, since the SIL surrogate analyte and the true analyte have the same physicochemical properties in terms of sample extraction, chromatographic separation, MS ionization, fragmentation, and detection. However, this approach is not readily available, since another version of the SIL analyte is required as an internal standard for the assay, and access to two versions of the SIL analyte is very costly and time-consuming, especially for the analysis of proteins. Therefore, other approaches need to be developed for quantitative LC-MS / MS analysis of biomarkers, drugs, or their metabolites in the preclinical or clinical phases of drug development. Summary of the Invention
[0005] The present disclosure relates to an LC-MS / MS technique for quantifying the concentration of at least one analyte in a sample, the method comprising adding known quantities of one or more stable isotope labeled (SIL) analytes to a sample containing at least one analyte, and constructing one or more intra-sample calibration curves (ISCCs) by multiple isotopic species reaction monitoring (MIRM) of each added SIL analyte, where MIRM of a SIL analyte refers to multiple reaction monitoring of multiple isotopic transitions of the SIL analyte; an ISCC of each analyte is constructed within the sample based on a relationship between theoretical isotopic abundances (analyte concentration equivalents) calculated at the MIRM transitions and tandem mass spectrometry (MS / MS) peak areas measured at the corresponding MIRM transitions; quantifying the concentration of at least one analyte in the sample using the established ISCCs and the measured peak areas for the analytes from a liquid chromatography-tandem mass spectrometry (LC-MS / MS) process; and the tandem mass spectrometer is operated in a multiple reaction monitoring mode.
[0006] In some aspects, the analyte, the SIL analyte, and the naturally occurring isotopic species of the SIL analyte are ionized in a mass spectrometer to produce protonated (or deprotonated) parent ions of the analyte, the SIL analyte, and the naturally occurring isotopic species of the SIL analyte. In some aspects, the parent ion of the analyte, the parent ion of the SIL analyte, and the parent ion of the naturally occurring isotopic species of the SIL analyte are fragmented at the same cleavage site in the mass spectrometer to produce neural losses and daughter ions.
[0007] In some embodiments, the transitions from parent ions to daughter ions of the analyte are monitored in a mass spectrometer and the peak areas for the transitions from parent ions to daughter ions of the analyte are measured. In some aspects, selected multiple transitions from parent ions of the SIL analyte and parent ions of the naturally occurring isotopic species of the SIL analyte to daughter ions of the SIL analyte and daughter ions of the naturally occurring isotopic species of the SIL analyte are monitored in a mass spectrometer ("multiple isotopic species reaction monitoring" or "MIRM").
[0008] In some aspects, the peak area of each MIRM transition is measured, where the MIRM transitions include selected transitions from a parent ion of the SIL analyte and a parent ion of a naturally occurring isotopic species of the SIL analyte to a daughter ion of the SIL analyte and a daughter ion of a naturally occurring isotopic species of the SIL analyte.
[0009] In some aspects, an intra-sample calibration curve is generated based on the relationship between the measured peak areas of the SIL analytes and the MIRM transitions of the SIL analytes' naturally occurring isotopic species and the analyte concentration equivalents for each MIRM transition.
[0010] In some aspects, the analyte concentration equivalent for each MIRM transition is calculated from the theoretical isotopic abundance of the corresponding MIRM transition of the SIL analyte or the naturally occurring isotopic species of the SIL analyte, where the theoretical isotopic abundance is calculated using the method published in Analytical Chemistry, 2012, 84(11), 4844-4850, which is calculated based on the neural loss and daughter ion isotopic distribution of the SIL analyte. In another aspect, for a unit resolution triple quadrupole mass spectrometer, the (p+Z p +α) / Z p From (d+Z d +β) / Zd The theoretical isotope abundance for each MIRM transition (m / z) is calculated using the formula (I): (p+Z p +α) / Z p →(d+Z d +β) / Z d Isotope abundance in MIRM transitions = [(d+Z d +β) mass relative isotopic distribution of daughter ions* [Kinematic isotope distribution of neutral loss in the molecular weight of n+(α-β)] (I) [In the formula, m / z is the mass-to-charge ratio p is the monoisotopic mass of the parent molecule of the SIL analyte Z p is the charge number of the parent ion d is the monoisotopic mass of the daughter fragment of the SIL analyte Z d is the charge number of the daughter ion n is the monoisotopic mass of the neutral loss of the SIL analyte p=d+n α and β are integers, which are the number of additional neutrons in the parent ion and daughter ion, respectively, and α > 0, β > 0, and alpha > β Z p and Z d is an integer] Calculation is based on:
[0011] In some aspects, an isotope abundance calculator is available at worldwideweb.sisweb.com / mstools / isotope.html (accessed November 10, 2019). In some aspects, the maximum analyte concentration equivalent (ISCC "upper limit of quantitation" or "ULOQ") is calculated according to Equation (II): (M / V)*(M 分析物 / M SIL分析物 )ng / mL (II) [In the formula, M (ng) is the total amount of SIL analyte added to the sample; V is the sample volume (mL) before addition of the SIL analyte; M 分析物 is the molecular weight of the analyte; M SIL分析物 is the molecular weight of the SIL analyte] Calculation is based on:
[0012] In some aspects, the one or more other analyte concentration equivalents in the MIRM transition are represented by formula (III): I a *ULOQ(ng / ml) (III) [In the formula, I a is the calculated theoretical isotopic abundance of the MIRM transition of the SIL analyte or a naturally occurring isotopic species of the SIL analyte. Calculation is based on:
[0013] The method of the present disclosure is useful for detecting or quantifying an analyte that is a protein with the corresponding SIL analyte. In some aspects, the analyte is a protein or peptide. In some aspects, the SIL analyte is a stable isotope labeled protein or peptide. In some aspects, the parent ion of the analyte and the parent of the SIL analyte comprise at least about 3 amino acids, at least about 4 amino acids, at least about 5 amino acids, at least about 6 amino acids, at least about 7 amino acids, at least about 8 amino acids, at least about 9 amino acids, at least about 10 amino acids, at least about 11 amino acids, at least about 12 amino acids, at least about 13 amino acids, at least about 14 amino acids, at least about 15 amino acids, at least about 16 amino acids, at least about 17 amino acids, at least about 18 amino acids, at least about 19 amino acids, or at least about 20 amino acids.
[0014] In some aspects, the analyte parent ion and the SIL analyte parent ion comprise an amino acid sequence of 4-20 amino acids, 4-15 amino acids, 5-15 amino acids, 4-14 amino acids, 5-14 amino acids, 5-13 amino acids, 5-12 amino acids, 6-15 amino acids, 6-14 amino acids, 6-13 amino acids, 6-12 amino acids, 6-11 amino acids, 6-10 amino acids, 6-9 amino acids, 6-8 amino acids, 7-15 amino acids, 7-14 amino acids, 7-13 amino acids, 7-12 amino acids, 7-11 amino acids, 7-10 amino acids, or 7-9 amino acids. In some aspects, the analyte is an antibody. In another aspect, the analyte is a fusion protein. In some aspects, the analyte is a fusion protein comprising a protein and a heterologous moiety. In another aspect, the analyte is an Fc fusion protein. In some aspects, the analyte is PD-1, PD-L1, CD73, an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CD73 antibody, or any combination thereof.
[0015] The methods of the present disclosure are also useful for detecting or quantifying analytes that are small molecules. In some aspects, the analyte is a small molecule. In some aspects, the SIL analyte is a stable isotope labeled small molecule. In some aspects, a small molecule has a molar mass of at least about 100 g / mol, at least about 200 g / mol, at least about 300 g / mol, at least about 400 g / mol, at least about 500 g / mol, at least about 600 g / mol, at least about 700 g / mol, at least about 800 g / mol, at least about 900 g / mol, at least about 1000 g / mol, at least about 1100 g / mol, at least about 1200 g / mol, at least about 1300 g / mol, at least about 1400 g / mol, at least about 1500 g / mol, at least about 1600 g / mol, at least about 1700 g / mol, at least about 1800 g / mol, at least about 1900 g / mol, or at least about 2000 g / mol.
[0016] The disclosed methods relate to the use of isotopically labeled SIL analytes. In some aspects, the SIL analytes comprise at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, or at least about 20 stable isotope labels.
[0017] In some aspects, the SIL analyte comprises from about 3 to about 20 isotopic labels, from about 3 to about 19 isotopic labels, from about 3 to about 15 isotopic labels, from about 3 to about 10 isotopic labels, from about 3 to about 8 isotopic labels, from about 3 to about 7 isotopic labels, from about 3 to about 6 isotopic labels, from about 4 to about 15 isotopic labels, from about 4 to about 10 isotopic labels, from about 4 to about 8 isotopic labels, from about 4 to about 7 isotopic labels, from about 4 to about 6 isotopic labels, from about 5 ... about 8 isotopic labels, about 5 to about 7 isotopic labels, about 6 to about 10 isotopic labels, about 6 to about 8 isotopic labels, about 7 to about 16 isotopic labels, about 7 to about 16 isotopic labels, about 8 to about 16 isotopic labels, about 8 to about 15 isotopic labels, about 9 to about 15 isotopic labels, about 9 to about 14 isotopic labels, about 10 to about 14 isotopic labels, about 10 to about 13 isotopic labels, or about 11 to about 13 isotopic labels.
[0018] The selection of MIRM transitions for measurement is a critical element of the disclosed methods to ensure stable and accurate assay performance. In some aspects, each of the relative peak areas measured at the MIRM transitions of the SIL analyte has a deviation of less than 15% from the theoretical isotopic abundance calculated at the corresponding MIRM transition of the SIL analyte or a naturally occurring isotopic species of the SIL analyte.
[0019] In some aspects, at least one of the relative peak areas measured at the MIRM transitions deviates from the theoretical isotopic abundance calculated at the corresponding MIRM transition of the SIL analyte or a naturally occurring isotopic species of the SIL analyte by less than 14%, less than 13%, less than 12%, less than 11%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.1%, less than 0.01%, less than 0.001%, or less than 0.0001%.
[0020] In some aspects, the number of MIRM transitions is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20. In some aspects, the number of MIRM transitions is between 4 and 15.
[0021] In some aspects, the analyte concentration equivalents of the largest and smallest MIRM transitions of a SIL analyte differ by at least about 10, at least about 100, at least about 200, at least about 300, at least about 400, at least about 500, at least about 600, at least about 700, at least about 800, at least about 900, at least about 1000, at least about 1100, at least about 1200, at least about 1300, at least about 1400, at least about 1500, at least about 1600, at least about 1700, at least about 1800, at least about 1900, or at least about 2000 fold.
[0022] In some aspects, the calculated theoretical isotopic abundances of two selected MIRM transitions are at least 0.01%, at least 0.05%, at least 0.1%, at least 0.5%, at least 1%, at least 1.5%, at least 2%, at least 2.5%, at least 3%, at least 3.5%, at least 4%, at least 4.5%, at least 5%, at least 5.5%, at least 6%, at least 6.5%, at least 7%, at least 7.5%, at least 8%, at least 8.5%, at least 9%, at least 9.5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least about 50% apart.
[0023] In some aspects, the SIL analyte contains less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, or less than 0.1% of unlabeled analyte.
[0024] In some aspects, the label is 2 H, 13 C. 15 N, 33 S, 34 S, 36 S, 17 O, or 18 It is O.
[0025] The method of the present disclosure relates to mass spectrometry, in which an ion source is used to ionize analytes (molecules). In some aspects, one or more of the protonated or deprotonated molecules are singly charged, doubly charged, triply charged, or more. In some aspects, the mass spectrometer is a triple quadrupole mass spectrometer, including Q1, Q2, and Q3. In some aspects, the resolution used for Q1 and Q3 is unit resolution. In other aspects, the resolution used for Q1 and Q3 is higher than unit resolution. In other aspects, the resolution used for Q1 and Q3 is different. In other aspects, the resolution used for Q1 is higher than unit resolution of Q3.
[0026] In some aspects, an intra-sample calibration curve (ISCC) composition (ie, a known amount of a SIL analyte) is added prior to or during sample preparation.
[0027] The methods of the present disclosure are highly effective and improve the amount of instrument time required, especially when an external calibration curve does not need to be run on the instrument. In some aspects, the methods reduce the total instrument run time. In some aspects, no external calibration curve is used. In some aspects, the analyte is a biomarker. In some aspects, the analyte is a metabolite. In some aspects, the analyte is a small molecule drug. In some aspects, the analyte is a peptide. In some aspects, the analyte is a protein.
[0028] The disclosed methods are effective for detection or quantification of analytes from a variety of sources, such as biological sources. In some aspects, the sample is serum, tissue, biopsy tissue, formalin-fixed / paraffin-embedded (FFPE), plasma, saliva, cerebrospinal fluid, tears, urine, synovial fluid, dried blood spots, or any combination thereof.
[0029] In some aspects, the analyte is CD73 or a portion thereof. In some aspects, the SIL analyte is V[Ile( 13 C 6 , 15 N)]YPAVEGR (SEQ ID NO: 1). In some aspects, the analyte is PD-1 or a portion thereof. In some aspects, the SIL analyte is LAAFPED[Arg( 13 C 6 , 15 N 4 )] (SEQ ID NO:2). In some aspects, the analyte is PD-L1 or a portion thereof. In some aspects, the SIL analyte is LQDAG[Val( 13 C 5 , 15 N)]YR (SEQ ID NO:3). In some aspects, the analyte is daclatasvir. In some aspects, the SIL analyte is13 C 2 15 N 4 -Daclatasvir.
[0030] The disclosed methods disclose compositions that include an intra-sample calibration curve (ISCC), where the ISCC is constructed by multiple isotope species reaction monitoring (MIRM) of a stable isotope labeled analyte.
[0031] The disclosed method also discloses a method for quantifying the concentration of at least one analyte in a research sample, comprising spiking one or more known amounts of one or more analytes into a blank matrix sample to generate one or more single sample multi-point external calibration curves (OSMECC) by multiple isotopic species reaction monitoring (MIRM) of each spiked analyte, where MIRM of an analyte refers to multiple reaction monitoring of multiple isotopic transitions of the analyte; and OSMECC of each analyte is calculated based on the theoretical isotopic abundance (analyte concentration equivalent) at the MIRM transition and the corresponding isotopic abundance at the MIRM transition. A correlation coefficient is established in a blank matrix sample based on the relationship of the measured tandem mass spectrometry (MS / MS) peak areas (or peak area ratios, if an internal standard is used in the assay) in the blank matrix sample; at least one concentration in the study sample is quantified using the peak areas (or peak area ratios, if an internal standard is used in the assay) measured for the analyte from an established OSMECC and liquid chromatography-tandem mass spectrometry (LC-MS / MS) process; the peak area ratio of the analyte is the peak area of the analyte divided by the peak area of the internal standard; and the tandem mass spectrometry is operated in multiple reaction monitoring mode.
[0032] In some aspects, the analyte concentration equivalent for each MIRM transition of the analyte is calculated from the theoretical isotopic abundance of the corresponding MIRM transition of the analyte or a naturally occurring isotopic species of the analyte, where the theoretical isotopic abundance is calculated using the method published in Analytical Chemistry, 2012, 84(11), 4844-4850, which is based on neutral loss and the isotopic distribution of daughter ions of the analyte.
[0033] In some aspects, for a unit resolution triple quadrupole mass spectrometer, the (p+Z p +α) / Z p From (d+Z d +β) / Z d The theoretical isotope abundance for each MIRM transition (m / z) is calculated using the formula (I): (p+Z p +α) / Z p →(d+Z d +β) / Z d Isotope abundance in MIRM transitions = [(d+Z d +β) mass relative isotopic distribution of daughter ions* [Relative isotopic distribution of neutral losses in n+(α-β) masses] (I) [In the formula, m / z is the mass-to-charge ratio p is the monoisotopic mass of the analyte parent molecule Z p is the charge number of the parent ion d is the monoisotopic mass of the daughter fragment of the analyte Z d is the charge number of the daughter ion n is the monoisotopic mass of the neutral loss of the analyte p=d+n α and β are integers, and α > 0, β > 0, and alpha > β Z p and Z d is an integer] Calculation is based on:
[0034] In some aspects, the isotope distribution calculator is worldwideweb.sisweb.com / mstools / isotope.html (accessed November 10, 2019). In some aspects, the maximum analyte concentration equivalent (ISCC "upper limit of quantitation" or "ULOQ") is calculated according to Equation (II): (M / V)*ng / mL (IV) [In the formula, M (ng) is the total amount of analyte added to the sample; V is the sample volume (mL) before addition of analyte] Calculation is based on:
[0035] In some aspects, the one or more other analyte concentration equivalents in the MIRM transition are represented by formula (III): I a *ULOQ(ng / mL) (III) [In the formula, I a is the calculated theoretical isotopic abundance of the MIRM transition of the analyte or a naturally occurring isotopic species of the analyte. Calculation is based on:
[0036] In some aspects, the analyte is a protein or peptide. In some aspects, the parent ion of the analyte comprises at least about 3 amino acids, at least about 4 amino acids, at least about 5 amino acids, at least about 6 amino acids, at least about 7 amino acids, at least about 8 amino acids, at least about 9 amino acids, at least about 10 amino acids, at least about 11 amino acids, at least about 12 amino acids, at least about 13 amino acids, at least about 14 amino acids, at least about 15 amino acids, at least about 16 amino acids, at least about 17 amino acids, at least about 18 amino acids, at least about 19 amino acids, or at least about 20 amino acids. In some aspects, the parent ion of the analyte comprises an amino acid sequence of 4-20 amino acids, 4-15 amino acids, 5-15 amino acids, 4-14 amino acids, 5-14 amino acids, 5-13 amino acids, 5-12 amino acids, 6-15 amino acids, 6-14 amino acids, 6-13 amino acids, 6-12 amino acids, 6-11 amino acids, 6-10 amino acids, 6-9 amino acids, 6-8 amino acids, 7-15 amino acids, 7-14 amino acids, 7-13 amino acids, 7-12 amino acids, 7-11 amino acids, 7-10 amino acids, or 7-9 amino acids. In some aspects, the analyte is an antibody. In some aspects, the analyte is a fusion protein. In some aspects, the analyte is PD-1, PD-L1, CD73, an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CD73 antibody, or any combination thereof. In some aspects, the analyte is a small molecule.
[0037] In some aspects, a small molecule has a molar mass of at least about 100 g / mol, at least about 200 g / mol, at least about 300 g / mol, at least about 400 g / mol, at least about 500 g / mol, at least about 600 g / mol, at least about 700 g / mol, at least about 800 g / mol, at least about 900 g / mol, at least about 1000 g / mol, at least about 1100 g / mol, at least about 1200 g / mol, at least about 1300 g / mol, at least about 1400 g / mol, at least about 1500 g / mol, at least about 1600 g / mol, at least about 1700 g / mol, at least about 1800 g / mol, at least about 1900 g / mol, or at least about 2000 g / mol. In some aspects, the number of MIRM transitions is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20. In some aspects, the number of MIRM transitions is between 2 and 20. In some aspects, the analyte concentration equivalents of the maximum and minimum MIRM differ by at least about 10, at least about 100, at least about 200, at least about 300, at least about 400, at least about 500, at least about 600, at least about 700, at least about 800, at least about 900, at least about 1000, at least about 1100, at least about 1200, at least about 1300, at least about 1400, at least about 1500, at least about 1600, at least about 1700, at least about 1800, at least about 1900, or at least about 2000 times.In some aspects, the calculated theoretical isotopic abundances of two selected MIRM transitions are at least 0.01%, at least 0.05%, at least 0.1%, at least 0.5%, at least 1%, at least 1.5%, at least 2%, at least 2.5%, at least 3%, at least 3.5%, at least 4%, at least 4.5%, at least 5%, at least 5.5%, at least 6%, at least 6.5%, at least 7%, at least 7.5%, at least 8%, at least 8.5%, at least 9%, at least 9.5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least about 50% apart. [Brief description of the drawings]
[0038] [Figure 1] Figure 1 shows a schematic diagram of the MIRM-ISCC-MS / MS methodology using a surrogate peptide of PD-L1 as an example. The amount of SIL analyte is added based on the expected concentration of the analyte to generate an appropriate calibration curve. Line 1 shows SIL analyte MIRM channel 1 (m / z: 464.2→686.4), 100% isotope abundance: SIL analyte concentration of 100 ng / mL (equivalent to 99.4 ng / mL analyte concentration); Line 2 shows SIL analyte MIRM channel 2 (m / z: 464.7→687.4), 30.0% isotope abundance: SIL analyte concentration of 30.0 ng / mL (equivalent to 29.8 ng / mL analyte concentration); / mL analyte concentration equivalent); line 3 shows SIL analyte MIRM channel 3 (m / z: 465.2 → 688.4), isotope abundance 6.63%: SIL analyte concentration of 6.63 ng / mL (analyte concentration equivalent of 6.59 ng / mL); line 4 shows analyte selected reaction monitoring (SRM) channel (m / z: 461.2 → 680.4), measured concentration: 56.8 ng / mL.
[0039] [Diagram 2]Figures 2A and 2B show representative chromatograms of 10 MIRM channels of SIL CD73 peptide and one selected reaction monitoring (SRM) channel of CD73 peptide. These 10 MIRM channels are used to construct an ISCC for quantitative analysis of CD73. Figure 2A is a reduced view; Figure 2B is an enlarged view.
[0040] [Diagram 3] FIG. 3 shows the LC-MS / MS bioanalysis workflow for one-sample multipoint external calibration curve (OSMECC) and isotopic sample dilution.
[0041] [Figure 4] Figures 4A and 4B. Figure 4A shows an overview of the MRM and MIRM transitions monitored for the multi-sample external calibration curve, one-sample multipoint external calibration curve (OSMECC), in-sample calibration curve (ISCC), and isotopic sample dilution for the measurement of daclatasvir. Figure 4B shows the calibration curve performance for the two multi-sample external calibration curves and two one-sample multipoint external calibration curves used, as well as the two ISCCs.
[0042] [Diagram 5] Figures 5A and 5B. Figure 5A shows the accuracy and precision of the data for QC samples quantified using multi-sample external calibration curves, one-sample multi-point external calibration curves, and ISCC. Both QC samples with concentrations within the calibration curve range (1, 3, 40, 500, and 800 ng / mL) and those with concentrations above the calibration curve range (5000 and 20000 ng / mL) were tested. However, the 5000 and 20000 ng / mL QC samples were physically diluted (100 and 200 times, respectively) into the calibration curve range during sample preparation. Figure 5B shows the accuracy and precision of the data for QC samples quantified using isotopic sample dilution. Only QC samples with concentrations above the calibration curve range (5000, 20000, and 50000 ng / mL) were tested.
[0043] Detailed Description of the Invention The present disclosure provides a highly effective approach for quantifying the concentration of an analyte via LC-MS / MS. Specifically, the approach uses an in-sample calibration curve (ISCC) using a stable labeled isotope (SIL) to measure the concentration of the analyte in a sample. A feature of the present disclosure is that by using an ISCC instead of an external calibration curve, the total run time of the LC-MS / MS instrument can be reduced. Furthermore, because the ISCC is present in the sample itself, the method of the present disclosure eliminates the need to use a real biological matrix to create an external calibration curve, simplifying the quantitative LC-MS / MS bioanalysis process.
[0044] As shown in the examples, the approach is effective to quantify analyte concentrations and generate concentration curves via MIRM monitoring of isotopic transitions. In some aspects, the disclosure provides a method of adding a SIL analyte to a sample containing the analyte, where the analyte can be quantified by ISCC generated from "multiple isotopic species reaction monitoring" or "MIRM" of the SIL analyte. In some aspects, the disclosure provides a method of analyzing protein analytes by using stable isotope labeled proteins or protein fragments. In some aspects, the disclosure provides a method of quantifying the concentration of an antibody. In another aspect, the disclosure provides a method of analyzing small molecules using stable isotope labeled variants of the small molecules.
[0045] I. Terminology The term "and / or" used herein should be interpreted as a specific disclosure of each of two specific features or components, whether or not the other is present. Thus, the term "and / or" used herein in phrases such as "A and / or B" is intended to include "A and B", "A or B", "A" (single), and "B" (single). Similarly, the term "and / or" used in phrases such as "A, B, and / or C" is intended to include each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (single); B (single); and C (single).
[0046] Whenever an aspect is described herein with the word "comprising," it will be understood that other similar aspects described with "consisting of" and / or "consisting essentially of" are also provided.
[0047] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure pertains.For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and the Oxford Dictionary Of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press provide those skilled in the art with a general dictionary for many terms used in this disclosure.
[0048] Units, prefixes, and symbols are shown in the format accepted by the International System of Units (SI). Numeric ranges are inclusive of the numerical values that define the range. The headings provided herein are not intended to limit the various aspects of the disclosure, which may be understood by reference to the entire specification. Thus, the terms defined immediately below are more fully defined by reference to the entire specification.
[0049] The use of the alternative (e.g., "or") should be understood to mean either one, both, or any combination thereof of the alternatives. As used herein, the indefinite article "a" or "an" should be understood to mean "one or more" of any described or listed elements.
[0050] The term "about" or "essentially consists of" refers to a value or composition that is within an acceptable error range for a particular value or composition as determined by one of ordinary skill in the art, which will depend in part on the limitations of the method of measuring or determining the value or composition, i.e., the detection system. For example, "about" or "essentially consists of" can mean within or more than one standard deviation, per practice in the art. Alternatively, "about" or "essentially consists of" can mean a range of up to 10%. Furthermore, particularly with respect to biological systems or processes, the term can mean up to an order of magnitude or up to 5-fold. When a particular value or composition is set forth in the present application and claims, unless otherwise stated, the meaning of "about" or "essentially consists of" should be presumed to be within an acceptable error range for that particular value or composition.
[0051] Any concentration range, percentage range, ratio range, or integer range used herein should be understood to include any integer value within the recited range, and, where appropriate, fractions thereof (such as tenths and hundredths of integers), unless specifically stated otherwise.
[0052] As used herein, a "biomarker" is virtually any detectable compound, such as a protein, peptide, proteoglycan, glycoprotein, lipoprotein, carbohydrate, lipid, nucleic acid (e.g., DNA, such as cDNA or replicative DNA, or RNA, such as mRNA), organic or inorganic chemical, natural or synthetic polymer, small molecule (e.g., metabolite), or a discriminating molecule or discriminating fragment of any of the foregoing present in or derived from a biological sample, or any other characteristic that is objectively measured and evaluated as a normal biological process, a pathogenic process, or a pharmaceutical response to a therapeutic intervention, or a symptom thereof.
[0053] As used herein, "metabolites" refer to any intermediates and products of metabolism. The presence of a drug metabolite is a reliable indicator that a person has used the metabolite's "parent" drug. Metabolites can be biomarkers.
[0054] As used herein, "metabolic profile" refers to any defined set of quantification values of metabolites that can be used for comparison with a reference value or profile obtained from another sample or group of samples.
[0055] As used herein, the term "isotopic species" refers to a composition that differs from a parent molecule in that at least one atom has a different number of neutrons.
[0056] As used herein, the term "analyte" is used in its broadest sense to include any molecule or protein (either natural or recombinant) present in a mixture for which analysis or quantification is desired. Such analytes include, but are not limited to, small molecules, enzymes, hormones, growth factors, cytokines, peptides, immunoglobulins (e.g., antibodies), and / or any fusion proteins.
[0057] As used herein, the terms "isotope" and "isotopic species" are used interchangeably and refer to a molecule that has a different isotopic composition compared to a parent molecule.
[0058] The term "analyte equivalent" or "analyte concentration equivalent" as used herein refers to the calculated concentration of a SIL analyte used to construct an intra-sample calibration curve (ISCC) after adjusting for the difference in mass between the SIL analyte and the analyte. The ISCC calibration curve is constructed based on MIRM measurements of the SIL analyte in parallel with the determination of the peak area of each MIRM. The calculated concentration curve must be adjusted to account for these small mass differences due to the difference in mass between the SIL analyte and the unlabeled analyte while adjusting for isotopic abundance. A representative ISCC concentration curve is shown in FIG. 1, where the SIL analyte concentration is adjusted to account for the difference in mass and isotopic abundance. For the maximum concentration of the concentration curve (upper limit of quantitation "ULOQ"), the adjustment of the sample to calculate the analyte equivalent is represented as point 1 in FIG. 1 and is calculated using equation (II): (M / V)*(M 分析物 / M SIL分析物 )ng / mL (II) [In the formula, M (ng) is the total amount of SIL analyte added to the sample; V is the sample volume (mL) before addition of the SIL analyte; M 分析物 is the molecular weight of the analyte; M SIL分析物 is the molecular weight of the SIL analyte] Calculation is based on:
[0059] For example, if a SIL analyte is added at a known concentration of 100 ng / mL and the MIRM has 100% isotopic abundance, the analyte concentration equivalent is 99.4 ng / mL, which is also the ULOQ, as shown in Figure 1 as data point 1. The adjustment of the sample for the remaining analyte concentration equivalents of the concentration curve is shown in Figure 1 at points 2 and 3 and is given by equation (III): I a *ULOQ(ng / ml) (III) [In the formula, I a is the calculated theoretical isotopic abundance of the MIRM transition of the SIL analyte or a naturally occurring isotopic species of the SIL analyte. Calculation is based on:
[0060] As used herein, the term "parent ion" or "precursor ion" refers to a charged molecular moiety that can dissociate to produce fragments, one or more of which may be charged and one or more of which may be neutral species. A parent ion may be a molecular ion or a charged fragment of a molecular ion.
[0061] The term "daughter ion" as used herein refers to a charged product of a reaction of a particular parent (precursor) ion. In general, such an ion is directly related to a particular precursor ion and may relate to the unique state of the precursor ion. The reaction does not necessarily involve fragmentation, but may involve, for example, a change in the number of charges carried. Thus, a fragment ion is a daughter ion, but not all daughter ions are fragment ions.
[0062] As used herein, the term "neutral loss" refers to the neutrally charged mass lost during the reaction of a particular parent (precursor) ion during the operation of a mass spectrometer.
[0063] The term "non-peptide molecule" as used herein is intended in the broadest sense and may include small molecules and small molecule drugs. "Small molecule" or "small molecule drug" is used broadly herein to refer to organic, inorganic, or organometallic compounds that generally have a molecular weight of less than about 1000-2000 g / mol, although this characteristic is not intended to limit the scope of the present invention. "Small molecule" may also refer to non-peptide, non-oligomeric organic compounds that are synthesized in the laboratory or occur naturally. Examples of "small molecules" include, but are not limited to, taxol, clopidogrel, and apixaban. Other examples of small molecules include dapagliflozin, saxagliptin, temsavir, ledipasvir, sofosbuvir, and rosuvastatin.
[0064] The term "chromatography" refers to any type of technique that separates molecules (e.g., antibodies) from other molecules (e.g., contaminants) present in a mixture. Molecules are usually separated from other molecules (e.g., contaminants) as a result of differences in the speed at which individual molecules of the mixture move through a stationary solvent under the influence of a mobile phase or in a binding and elution process. The terms "matrix" or "chromatography matrix" are used interchangeably herein and refer to any type of adsorbent, resin, or solid phase that separates molecules from other molecules present in a mixture in a separation process. Non-limiting examples include particulate, monolithic, or fibrous resins and membranes that can be used in columns or cartridges. Examples of materials that form matrices include polysaccharides (such as agarose and cellulose); and other mechanically stable matrices such as silica (e.g., controlled pore glass), poly(styrenedivinyl)benzene, polyacrylamide, ceramic particles, and derivatives of any of the above. Examples of typical matrix types suitable for the methods of the present disclosure are cation exchange resins, affinity resins, anion exchange resins, or mixed phase resins. A "ligand" is a functional group that binds to a chromatography matrix and determines the binding properties of the matrix. Examples of "ligands" include, but are not limited to, ion exchange groups, hydrophobic interaction groups, hydrophilic interaction groups, thiophilic interaction groups, metal affinity groups, affinity groups, bioaffinity groups, and mixed phase groups (combinations of the above). Some preferred ligands that can be used herein include, but are not limited to, strong cation exchange groups such as sulfopropyl, sulfonic acid; strong anion exchange groups such as trimethylammonium chloride; weak cation exchange groups such as carboxylic acid; weak anion exchange groups such as N5N diethylamino or DEA; hydrophobic interaction groups such as phenyl, butyl, propyl, hexyl; and affinity groups such as protein A, protein G, and protein L. To make this disclosure more easily understandable, some terms are first defined.As used herein, unless expressly stated otherwise herein, each of the following terms shall have the meaning set forth below. Additional definitions are set forth throughout the specification.
[0065] The term "affinity chromatography" refers to a protein separation technique in which a molecule (e.g., an Fc region-containing molecule or an antibody) specifically binds to a ligand specific for the molecule. Such a ligand is commonly referred to as a biospecific ligand. In some aspects, the biospecific ligand (e.g., protein A, or a functional variant thereof) is covalently attached to a chromatography matrix material and is accessible to the molecule in solution when the solution is in contact with the chromatography matrix. The molecule generally has a specific binding affinity to the biospecific ligand during the chromatography step, while other solutes and / or proteins in the mixture do not appreciably or specifically bind to the ligand. The binding of the molecule to the immobilized ligand allows the contaminating proteins or protein impurities to pass through the chromatography matrix while the molecule remains specifically bound to the immobilized ligand of the solid phase material. The specifically bound molecule is then removed in active form from the immobilized ligand under appropriate conditions (e.g., low pH, high pH, high salt, competing ligands, etc.) and passed through the chromatography column with an elution buffer that is free of the contaminating proteins or protein impurities that were previously able to pass through the column. Any component can be used as a ligand to purify the respective specific binding protein, e.g., an antibody. However, in various methods of the present disclosure, for an Fc region-containing target protein, protein A is used as the ligand. The elution conditions of a target protein (e.g., an Fc region-containing protein) from a biospecific ligand (e.g., protein A) can be readily determined by one of skill in the art. In some aspects, protein G or protein L or functional variants thereof can be used as the biospecific ligand. In some aspects, a biospecific ligand such as protein A is used in the pH range of 5-9 for binding to the Fc region-containing protein, washing, or re-equilibration of the biospecific ligand / target protein conjugate, and then eluted with a buffer containing at least one salt and having a pH of about 4 or less.
[0066] The terms "purify," "separate," or "isolate" are used interchangeably herein and refer to increasing the purity of a molecule from a composition or sample that contains the molecule and one or more impurities. Generally, the degree of purity of a molecule is increased by removing (completely or partially) at least one impurity from the composition.
[0067] As used herein, the term "chromatography column" or "column" in reference to chromatography refers to a container, often in the form of a cylinder or hollow post, that is packed with a chromatography matrix or resin, which is a material that provides the physical and / or chemical properties used in purification.
[0068] The terms "ion exchange" and "ion exchange chromatography" refer to a chromatographic process in which an ionizable solute of interest (e.g., a molecule in a mixture) interacts with an oppositely charged ligand attached (e.g., by covalent bonding) to a solid-phase ion exchange material under suitable pH and conductivity conditions, such that the solute of interest interacts nonspecifically with more or less charged compounds than solute impurities or contaminants in the mixture. Contaminant solutes in the mixture can be washed off the column of ion exchange material, or they can bind to or be rejected from the resin faster or slower than the solute of interest. "Ion exchange chromatography" specifically includes cation exchange (CEX), anion exchange (AEX), and mixed-phase chromatography.
[0069] "Cation exchange resin" or "cation exchange membrane" refers to a solid phase that is negatively charged and has free cations for exchange with cations in an aqueous solution passed over or through the solid phase. Any negatively charged ligand bound to a suitable solid phase to form a cation exchange resin can be used, e.g., carboxylates, sulfonates, and others described below. Commercially available cation exchange resins include, but are not limited to, sulfonate-based groups (e.g., MonoS, MiniS, Source 15S and 30S from GE Healthcare, SP SEPHAROSE® Fast Flow, SP SEPHAROSE® High Performance, TOYOPEARL® SP-650S and SP-650M from Tosoh, MACRO-PREP® High S from BioRad, Ceramic HyperD S, TRISACRYL® M and LS SP and Spherodex LS SP from Pall Technologies); sulfoethyl-based groups (e.g., FRACTOGEL® SE from EMD, POROS® S-10 and S-20 from Applied Biosystems); sulfopropyl-based groups (e.g., TSK Gel SP 5PW and SP-5PW-HR from Tosoh, POROS® HS-20, HS 50, and from Life Technologies). POROS® XS; sulfoisobutyl-based groups (e.g., FRACTOGEL® EMD SO from EMD 3 -); sulfoxyethyl-based groups (e.g., SE52, SE53 and Express-Ion S from Whatman); carboxymethyl-based groups (e.g., SEPHAROSE® Fast Flow from GE HealthcareC, Hydrocell CM from Biochrom Labs Inc., MACRO-PREP® CM from BioRad, Ceramic HyperD CM, TRISACRYL® M CM, TRISACRYL® LS CM, Matrx CELLUFINE® C500 and C200 from MilliporeM, M52, CM32, CM23 and Express-Ion C from WhatmanC, TOYOPEARL® CM-650S, CM-650M and CM-650C from Tosoh); sulfonic and carboxylic acid-based groups (e.g., BAKERBOND® Carboxy-Sulfon from JT Baker); carboxylic acid-based groups (e.g., J. WP CBX from T Baker, DOWEX® MAC-3 from Dow Liquid Separations, AMBERLITE® Weak Cation Exchangers, DOWEX® Weak Cation Exchanger, and DIAION® Weak Cation Exchangers from Sigma-Aldrich, and FRACTOGEL® EMD COO-- from EMD; sulfonic acid-based groups (e.g., Hydrocell SP from Biochrom Labs Inc., DOWEX® Fine Mesh Strong Acid Cation Resin from Dow Liquid Separations, JTUNOsphere S, WP Sulfonic from Baker, SARTOBIND® S membrane from Sartorius, AMBERLITE® Strong Cation Exchangers, DOWEX® Strong Cation and DIAION® Strong Cation Exchanger from Sigma-Aldrich; or those with orthophosphate-based groups (e.g., P11 from Whatman).
[0070] Other cation exchange resins include Poros HS, Poros XS, carboxymethylcellulose, BAKERBOND ABX™, sulfopropyl and sulfonyl immobilized agarose, MonoS, MiniS, Source 15S, 30S, SP SEPHAROSE®, CM SEPHAROSE®, BAKERBOND Carboxy-Sulfon, WP CBX, WP Sulfonic, Hydrocell CM, Hydrocel SP, UNOsphere S, Macro-Prep High S, Macro-Prep CM, Ceramic HyperD S, Ceramic HyperD CM, Ceramic HyperD Z, Trisacryl M CM, Trisacryl LS CM, Trisacryl M SP, Trisacryl LS SP, Spherodex LS SP, DOWEX Fine Mesh Strong Acid Cation Resin, DOWEX MAC-3, Matrex Cellufine C500, Matrex Cellufine C200, Fractogel EMD SO3-, Fractogel EMD SE, Fractogel EMD COO-, Amberlite Weak and Strong Cation Exchangers, Diaion Weak and Strong Cation Exchangers, TSK Gel SP-5PW-HR, TSK Gel SP-5PW, Toyopearl CM (650S, 650M, 650C), Toyopearl SP (650S, 650M, 650C), CM (23, 32, 52), SE(52, 53), P11, Express-Ion C, or Express-Ion S.
[0071] "Anion exchange resin" or "anion exchange membrane" refers to a solid phase that is positively charged and has one or more positively charged ligands attached to it. Any positively charged ligand, such as a quaternary amino group, attached to the solid phase suitable for forming an anion exchange resin can be used. Commercially available anion exchange resins include DEAE cellulose, POROS® PI 20, PI 50, HQ 10, HQ 20, HQ 50, D 50 from Applied Biosystems, SARTOBIND® Q, MonoQ, MiniQ, Source 15Q and 30Q, Q, DEAE and ANX SEPHAROSE® Fast Flow, Q SEPHAROSE® High Performance, QAE SEPHADEX® and FAST Q SEPHAROSE® from Sartorius (GE Healthcare), WP PEI, WP DEAM, WP QUAT from JT Baker, Hydrocell DEAE and Hydrocell QA from Biochrom Labs Inc., UNOsphere Q, MACRO-PREP® DEAE and MACRO-PREP® High Q from Biorad, Ceramic HyperD Q, ceramic HyperD DEAE, from Pall Technologies, TRISACRYL® M and LS DEAE, Spherodex LS DEAE, QMA SPHEROSIL® LS, QMA SPHEROSIL®.M and MUSTANG® Q, DOWEX® Fine Mesh Strong Base Type I and Type II Anion Resins and DOWEX® MONOSPHER E 77, weak base anion from Dow Liquid Separations, INTERCEPT® Q membrane, Matrex CELLUFINE® A200, A500, Q500, and Q800 from Millipore, FRACTOGEL® EMD TMAE, FRACTOGEL® EMD DEAE and FRACTOGEL® EMD DMAE from EMD, AMBERLITE® weak strong anion exchangers type I and II, DOWEX® weak and strong anion exchangers type I and II, DIAION® weak and strong anion exchangers type I and II, DUOLITE®, TSK gel Q and DEAE 5PW from Tosoh and 5PW-HR, TOYOPEARL® SuperQ-650S, 650M and 650C, QAE-550C and 650S, DEAE-650M and 650C, QA52, DE23, DE32, DE51, DE52, DE53, Express-Ion D or Express-Ion Q from Whatman, and SARTOBIND® Q (Sartorius Corporation, New York, USA).
[0072] Other anion exchange resins include POROS HQ, Q SEPHAROSE® Fast Flow, DEAE SEPHAROSE® Fast Flow, SARTOBIND® Q, ANX SEPHAROSE® 4 Fast Flow (high sub), Q SEPHAROSE® XL, Q SEPHAROSE® big beads, DEAE Sephadex A-25, DEAE Sephadex A-50, QAE Sephadex A-25, QAE Sephadex A-50, Q SEPHAROSE® high performance, Q SEPHAROSE® XL, Sourse 15Q, Sourse 30Q, Resourse Q, Capto Q, Capto DEAE, Mono Q, Toyopearl Super Q, Toyopearl DEAE, Toyopearl QAE, Toyopearl Q, Toyopearl GigaCap Q, TS gel SuperQ, TS gel DEAE, Fractogel EMD TMAE, Fractogel EMD TMAE HiCap, Fractogel EMD DEAE, Fractogel EMD DMAE, Macroprep High Q, Macro-prep-DEAE, Unosphere Q, Nuvia Q, PORGS PI, DEAE Ceramic HyperD, or Q Ceramic HyperD.
[0073] "Mass spectrometry" ("MS" or "mass-spec") is an analytical technique used to measure mass-to-charge ratio ions. This is accomplished by ionizing a sample, separating ions of different molecular weights, and recording their relative abundance by measuring the intensity of the ion flow. A typical mass spectrometer contains three parts: an ion source, a mass spectrometer, and a detection system. The ion source is the part of the mass spectrometer that ionizes the substance to be analyzed (the analyte). The ion source is then transported by a magnetic or electric field to the mass spectrometer where the ions are separated according to their mass-to-charge ratio (m / z). Many mass spectrometers use two or more mass spectrometers for tandem mass spectrometry (MS / MS). The detector records the charge induced, or the current produced, when the ions pass through or impact a surface. Mass spectrometry is the result of measuring the signal produced at the detector as the m / z ions are scanned by the mass spectrometer.
[0074] As used herein, the term "intra-sample calibration curve (ISCC)" refers to a calibration curve that is present in the sample matrix itself, rather than the external calibration curves traditionally used to perform, for example, LC-MS / MS analyses.
[0075] As used herein, the term "SIL analyte" or "stable isotope labeled analyte" refers to a compound that is an analyte or a fragment thereof that has been modified to include an isotopic element at one or more positions. The most common labeling technique is the use of stable isotopes. 13 C or 15 N can be used to label a compound at one or more positions. Other suitable stable isotopes include: 2 H, 33 S, 34 S, 36 S, 17 O, or 18 O is one example.
[0076] The term "multiple isotopic species reaction monitoring" or MIRM refers to a process by tuning a mass spectrometer to track specific multiple reaction monitoring (MRM) transitions from a parent ion and its isotopic species ion (parent ion with different neutrons) to its product ions with the same cleavage site, also referred to as "MIRM channel" or "MIRM transition". More generally, when only a single ion is measured using a mass spectrometer, the process is also called selected reaction monitoring (SRM). When multiple reactions are measured by SRM and multiple product ions are generated from one or more precursor ions, the process is known in the art as multiple reaction monitoring (MRM). In an SRM experiment in a triple quadrupole mass spectrometer, the first quadrupole (Q1) is set to pass only a specific m / z (precursor ion) of the expected species in the sample. The second quadrupole (i.e., Q2 or collision cell) is used to fragment the ions that have passed through Q1. The third quadrupole (Q3) is configured to pass only ions of a particular m / z (fragment ions) that correspond to the expected fragmentation products of the expected species to the detector. When many SRM experiments are performed, the process is called multiple reaction monitoring ("MRM").
[0077] As used herein, the term "MIRM transition", or parent-daughter ion transition pair, "PDITP", refers to a pair of m / z values that are tracked. Briefly, the daughter ion D(d+1.00783*Z d The monoisotopic mass of Z d is the charge number of the daughter ion) and the parent ion P(p+1.00783*Z) with neutral loss N(monoisotopic mass of n) p The monoisotopic mass of Z p is the charge number of the parent ion, and the monoisotopic mass of hydrogen is 1.00783 Da), the most abundant (100%) MIRM channels (m / z) are as follows: (p+1.00783*Z p ) / Z p→(d+1.00783*Z d ) / Z d
[0078] For a unit resolution triple quadrupole mass spectrometer using the most commonly used charge states (singly, doubly, and triply charged ions), this MIRM channel (m / z) can be simplified to: (p+Z p ) / Z p →(d+Z d ) / Z d
[0079] Isotope abundance (m / z) in adjacent MIRM channels (m / z): (p+Z p +α) / Z p →(d+Z d +β) / Z d can be calculated as follows: (p+Z p +α) / Z p →(d+Z d +β) / Z d isotope abundance in adjacent MIRM channels = [(d+Z d +β) mass relative isotopic distribution of daughter ions* [Relative isotopic distribution of neutral losses in the molecular weight of n+(α-β)] [In the formula, (1) p = d + n (2) α and β are integers that are the number of additional neutrons in the parent and daughter ions, respectively, and α > 0, β > 0, and alpha > β (3) Z p and Z d is an integer, (4) The isotopic distribution of a molecule can be obtained using an online calculator (worldwideweb.sisweb.com / mstools / isotope.html, accessed November 10, 2019), (5) At masses d (α = 0) and n (α-β = 0), respectively, the relative isotopic distributions of the daughter ions and neutral losses are 100%.
[0080] By using different combinations of α and β, (p+Z p +α) / Z p →(d+Z d +β) / Z d The isotope abundances in adjacent MIRM channels (m / z) of different sizes can be accurately calculated and measured.
[0081] Various aspects of the disclosure are described in further detail in the following subsections.
[0082] II.Quantitative method The present disclosure relates to a multi-isotope molecular species reaction monitoring-in-sample calibration correction-LC-MS / MS (MIRM-ISCC-LC-MS / MS) method, which allows for instant and accurate measurement of each individual sample without the use of external calibration curves, thereby eliminating the need for authentic biological matrices, simplifying the quantitative LC-MS / MS bioanalysis process and significantly reducing instrument time. Although the MIRM-ISCC-LC-MS / MS method can be applied to routine pharmacokinetic (PK) sample analysis in drug discovery and development, this method is particularly useful when authentic matrices are rarely available, such as biomarker measurement and quantitative proteomics, and when low throughput and long turnaround times are the main issues preventing the use of LC-MS / MS technology, such as clinical diagnostics in clinical diagnostic laboratories, and when calibration curve generation is cumbersome, such as fresh frozen FFPE tissue analysis. In addition, ISCC can also be used as an external calibration curve by spiking known amounts of unlabeled analyte in the blank matrix, so that the external calibration curve can be generated in only one sample, eliminating the need to prepare multiple samples for the external calibration curve.
[0083] Typically, the most abundant MIRM channel of an analyte is monitored in an LC-MS / MS assay for quantitative analysis. In addition to the MS / MS response observed in the most abundant MIRM channel due to the naturally occurring isotopes of an element, the isotopic abundance in the isotopic MIRM channel adjacent to the most abundant MIRM channel can be accurately calculated and measured by LC-MS / MS. Briefly, the daughter ion D(d+1.00783*Z d The monoisotopic mass of Z d parent ion P(p+1.00783*Z) with neutral loss N(monoisotopic mass of n) p The monoisotopic mass of Z p is the charge number of the parent ion, and the monoisotopic mass of hydrogen is 1.00783 Da), the most abundant (100%) MIRM channel (m / z) is as follows: (p+1.00783*Z p ) / Z p →(d+1.00783*Z d ) / Z d
[0084] For a unit resolution triple quadrupole mass spectrometer using the most commonly used charge states (singly, doubly, and triply charged ions), this MIRM channel (m / z) can be simplified to: (p+Z p ) / Z p →(d+Z d ) / Z d
[0085] Isotope abundance in adjacent MIRM channels (m / z): (p+Z p +α) / Z p →(d+Z d +β) / Z d can be calculated as follows: (p+Z p +α) / Z p →(d+Z d +β) / Z disotope abundance in adjacent MIRM channels = [(d+Z d +β) mass relative isotopic distribution of daughter ions* [Relative isotopic distribution of neutral losses in the molecular weight of n+(α-β)] [In the formula, (1) p = d + n (2) α and β are integers that are the number of additional neutrons in the parent and daughter ions, respectively, and α > 0, β > 0, and alpha > β (3) Z p and Z d is an integer, (4) The isotopic distribution of a molecule can be obtained using an online calculator (worldwideweb.sisweb.com / mstools / isotope.html (accessed November 10, 2019)). (5) At masses d (α=0) and n (α-β=0), respectively, the relative isotopic distributions of daughter ions and neutral losses are 100%.
[0086] By using different combinations of α and β, (p+Z p +α) / Z p →(d+Z d +β) / Z dThe isotope abundances in different adjacent MIRM channels (m / z) can be accurately calculated and measured. The isotope abundances from the most abundant MIRM channel (α=0 and β=0) to the least abundant MIRM channel can be 5-6 orders of magnitude higher. Theoretically, there should be a linear relationship between the MS / MS response (peak area) and the calculated theoretical isotope abundances in all adjacent MIRM channels over the entire range, since these isotope abundances arise from different isotope combinations of daughter ions and neutral losses, which have the "same" physicochemical properties. However, this linear relationship is limited by the detection limit of the mass spectrometer, as well as the linear range of most mass spectrometers. To maintain this linear relationship, the same mass spectrometer parameters, such as dwell time, collision energy (CE), and declustering potential (DP), must be set for all MIRM channels used for the SIL analytes and for the SRM channels used for the analytes.
[0087] This method demonstrates a completely new way to construct an intra-sample calibration curve (ISCC) for each study sample using isotope abundances in the multiisotope reactive monitoring (MIRM) channel for quantitative LC-MS / MS bioanalysis. There are many potential applications of the MIRM-ISCC-LC-MS / MS method, such as use in quantitative analysis of small molecules, peptides, proteins, biomarkers, quantitative proteomics, clinical diagnostic research, and other fields.
[0088] Absolute quantification in LC-MS proteomics using the isotope dilution principle was achieved by spiking each study sample with a known amount of SIL peptides (AQUA approach) or proteins (PSAQ approach). The peptide (or protein) concentration of a study sample could be calculated using the ratio of the peak area of the unlabeled peptide (or protein) to the peak area of the labeled peptide (or protein). However, this quantification approach is based on only one calibration point, which assumes that a linear relationship passing through the origin exists between the MS response (or response ratio) and the corresponding concentration.
[0089] Recently, to address this issue, Chiva et al. (66th ASMS Conference on Mass Spectrometry and Allied Topics, June 3-7, 2018, San Diego, CA, p ThP 481) reported that they developed an accurate and stable assay for absolute quantification of target peptides in formalin-fixed / paraffin-embedded (FFPE) samples by spiking a calibration curve into each study sample. The calibration curve was pre-generated with five different SIL peptide analytes (and 10, 16, 23, 33, and 39 total labeling sites for each SIL peptide analyte) at different concentrations ranging from 2 to 200 fmol. However, since multiple differently labeled peptide analytes with as many as 30-40 labeling sites are required for the analysis of one target peptide, this method is very costly and time-consuming, especially for quantitative proteomics of multiple target peptides.
[0090] A method useful in the present disclosure relates to detecting the presence and / or quantifying the concentration of at least one analyte in a sample, the method comprising spiking a sample containing at least one analyte with one or more known quantities of stable isotope labeled (SIL) analytes and constructing one or more in-sample calibration curves (ICSS) by multiple isotopic species reaction monitoring (MIRM) of each spiked SIL analyte, where MIRM of a SIL analyte refers to multiple reaction monitoring of multiple isotopic transitions of the SIL analyte; where an ISCC of each analyte is constructed within the sample based on a relationship between the theoretical isotopic abundance (analyte concentration equivalent) calculated at the MIRM transition and the tandem mass spectrometry (MS / MS) peak area measured at the corresponding MIRM transition; where the established ICSS and the measured peak area for the analyte from a liquid chromatography-tandem mass spectrometry (LC-MS / MS) process are used to quantify the concentration of the at least one analyte in the sample; where the tandem mass spectrometer is operated in a multiple reaction monitoring mode.
[0091] In some aspects, the analyte, SIL analyte, and naturally occurring isotopic species of the SIL analyte are ionized in a mass spectrometer to produce protonated (or deprotonated) parent ions of the analyte, SIL analyte, and naturally occurring isotopic species of the SIL analyte. In some aspects, the parent ions of the analyte, SIL analyte, and naturally occurring isotopic species of the SIL analyte are fragmented at the same cleavage sites in the mass spectrometer to produce neutral loss and daughter ions.
[0092] In some aspects, transitions from parent ions of the analyte to daughter ions are monitored in a mass spectrometer and the peak areas for the transitions from parent ions of the analyte to daughter ions are measured. In some aspects, selected multiple transitions from parent ions of the SIL analyte and parent ions of the naturally occurring isotopic species of the SIL analyte to daughter ions of the SIL analyte and daughter ions of the naturally occurring isotopic species of the SIL analyte are monitored in a mass spectrometer ("multiple isotopic species reaction monitoring" or "MIRM").
[0093] In some aspects, the peak area of each MIRM transition is measured, where the MIRM transition comprises a selected transition from a parent ion of the SIL analyte and a parent ion of a naturally occurring isotopic species of the SIL analyte to a daughter ion of the SIL analyte and a daughter ion of a naturally occurring isotopic species of the SIL analyte.
[0094] In some aspects, an intra-sample calibration curve is generated based on the relationship between the peak areas measured at the MIRM transitions of the SIL analyte and the naturally occurring isotopic species of the SIL analyte and the analyte concentrations equivalent to each MIRM transition.
[0095] In some aspects, the analyte concentration equivalent to each MIRM transition is calculated from the theoretical isotopic abundance of the corresponding MIRM transition of the SIL analyte or the naturally occurring isotopic species of the SIL analyte, where the theoretical isotopic abundance is calculated using the method published in Analytical Chemistry, 2012, 84(11), 4844-4850, where the method is calculated based on the neutral loss and daughter ion isotopic distribution of the SIL analyte. In another aspect, the (p+Z p +α) / Z p From (d+Z d +β) / Z dThe theoretical isotope abundance for each MIRM transition (m / z) is calculated using the formula (I): (p+Z p +α) / Z p →(d+Z d +β) / Z d Isotope abundance in MIRM transitions = [(d+Z d +β) mass relative isotopic distribution of daughter ions* [Relative isotopic distribution of neutral losses in n+(α-β) mass] (I) [In the formula, m / z is the mass-to-charge ratio p is the monoisotopic mass of the parent molecule of the SIL analyte Z p is the charge number of the parent ion d is the monoisotopic mass of the daughter fragment of the SIL analyte Z d is the charge number of the daughter ion n is the monoisotopic mass of the neutral loss of the SIL analyte p=d+n α and β are integers that are the number of additional neutrons in the parent and daughter ions, respectively, and α > 0, β > 0, and alpha > β Z p and Z d is an integer] Calculation is based on:
[0096] In some aspects, an isotope abundance calculator is available at worldwideweb.sisweb.com / mstools / isotope.html (accessed November 10, 2019). In some aspects, the maximum analyte concentration equivalent (ISCC "upper limit of quantitation" or "ULOQ") is calculated according to Equation (II): (M / V)*(M 分析物 / M SIL分析物 )ng / mL (II) [In the formula, M (ng) is the total amount of SIL analyte added to the sample; V is the sample volume (mL) before addition of the SIL analyte; M 分析物 is the molecular weight of the analyte; M SIL分析物 is the molecular weight of the SIL analyte] Calculation is based on:
[0097] In some aspects, the one or more other analyte concentration equivalents in the MIRM transition are represented by formula (III): I a *ULOQ(ng / ml) (III) [In the formula, I a is the calculated theoretical isotopic abundance of the MIRM transition of the SIL analyte or a naturally occurring isotopic species of the SIL analyte. Calculation is based on:
[0098] A method useful in the present disclosure relates to the use of a stable isotope labeled (SIL) analyte, which is added to a sample containing the analyte. The SIL analyte can then be monitored by MIRM technology and a concentration calibration curve can be constructed to quantify the concentration of the analyte present in the sample. In some aspects, the analyte is a protein or peptide, and the SIL analyte is a stable isotope labeled protein or peptide. In some aspects, the parent ion of ... Contains 1 amino acid, at least about 22 amino acids, at least about 23 amino acids, at least about 24 amino acids, at least about 25 amino acids, at least about 26 amino acids, at least about 27 amino acids, at least about 28 amino acids, at least about 29 amino acids, at least about 30 amino acids, at least about 31 amino acids, at least about 32 amino acids, at least about 33 amino acids, at least about 34 amino acids, at least about 35 amino acids, at least about 36 amino acids, at least about 37 amino acids, at least about 38 amino acids, at least about 39 amino acids, or at least about 40 amino acids.
[0099] In some aspects, the parent ion of the SIL analyte comprises an amino acid sequence of 4-40 amino acids, 4-35 amino acids, 5-35 amino acids, 4-34 amino acids, 5-34 amino acids, 5-33 amino acids, 5-32 amino acids, 6-35 amino acids, 6-34 amino acids, 6-33 amino acids, 6-32 amino acids, 6-31 amino acids, 6-30 amino acids, 6-29 amino acids, 6-28 amino acids, 7-35 amino acids, 7-34 amino acids, 7-33 amino acids, 7-32 amino acids, 7-31 amino acids, 7-30 amino acids, or 7-29 amino acids. In some aspects, the analyte or parent ion of the SIL analyte comprises an amino acid sequence of 7-11 amino acids. In some aspects, the parent ion of the SIL analyte comprises an amino acid sequence of 8-11 amino acids. In some aspects, the parent ion of the SIL analyte comprises an amino acid sequence of 8-10 amino acids. In some aspects, the parent ion of the SIL analyte comprises an amino acid sequence of 8-9 amino acids. In some aspects, the parent ion of the SIL analyte comprises an amino acid sequence of 6-9 amino acids. In some aspects, the parent ion of the SIL analyte comprises an amino acid sequence of 6-10 amino acids.
[0100] In some aspects, a parent ion of a SIL analyte comprises an amino acid sequence of 4-30 amino acids, 4-25 amino acids, 5-25 amino acids, 4-24 amino acids, 5-24 amino acids, 5-23 amino acids, 5-22 amino acids, 6-25 amino acids, 6-24 amino acids, 6-23 amino acids, 6-22 amino acids, 6-21 amino acids, 6-20 amino acids, 7-25 amino acids, 7-24 amino acids, 7-23 amino acids, 7-22 amino acids, 7-21 amino acids, or 7-20 amino acids.
[0101] In some aspects, a parent ion of a SIL analyte comprises an amino acid sequence of 4-20 amino acids, 4-15 amino acids, 5-15 amino acids, 4-14 amino acids, 5-14 amino acids, 5-13 amino acids, 5-12 amino acids, 6-15 amino acids, 6-14 amino acids, 6-13 amino acids, 6-12 amino acids, 6-11 amino acids, 6-10 amino acids, 6-9 amino acids, 6-8 amino acids, 7-15 amino acids, 7-14 amino acids, 7-13 amino acids, 7-12 amino acids, 7-11 amino acids, 7-10 amino acids, or 7-9 amino acids.
[0102] In some aspects, the SIL analyte is a stable isotope labeled protein or peptide. In some aspects, the parent ion of the SIL analyte comprises at least about 3 amino acids, at least about 4 amino acids, at least about 5 amino acids, at least about 6 amino acids, at least about 7 amino acids, at least about 8 amino acids, at least about 9 amino acids, at least about 10 amino acids, at least about 11 amino acids, at least about 12 amino acids, at least about 13 amino acids, at least about 14 amino acids, at least about 15 amino acids, at least about 16 amino acids, at least about 17 amino acids, at least about 18 amino acids, at least about 19 amino acids, or at least about 20 amino acids.
[0103] In some aspects, the analyte is an antibody. In another aspect, the analyte is a fusion protein. In another aspect, the analyte is a fusion protein comprising a protein and a heterologous moiety. In another aspect, the analyte is an Fc fusion protein. In some aspects, the analyte is PD-1, PD-L1, CD73, an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CD73 antibody, or any combination thereof. In some aspects, the analyte is an anti-GITR antibody, an anti-CXCR4 antibody, an anti-TIGIT antibody, an anti-OX40 antibody, an anti-LAG3 antibody, an anti-TIM3 antibody, an anti-IL8 antibody, or any combination thereof.
[0104] The disclosed method is effective for detecting and quantifying analytes that are proteins using corresponding SIL analytes. In some aspects, the analyte is an antibody. In some aspects, the analyte is CD73 or an anti-CD73 antibody, or a fragment thereof. In some aspects, the analyte is PD-1, or an anti-PD-1 antibody, such as nivolumab, or a fragment thereof. In some aspects, the analyte is PD-L1, or an anti-PD-L1 antibody, such as ipilimumab, or a fragment thereof. In some aspects, the analyte is an anti-OX40 (also known as CD134, TNFRSF4, ACT35, and / or TXGP1L) antibody (e.g., BMS986178, or MDX-1803), or a fragment thereof. In some aspects, the analyte is urocuplumab, or a fragment thereof. In some aspects, the analyte is BMS-986156, or a fragment thereof. In some aspects, the analyte is BMS-986016, or a fragment thereof. In some aspects, the analyte is BMS-986207, or a fragment thereof. In some aspects, the analyte is BMS-986253, or a fragment thereof. In some aspects, the analyte is BMS-986258, or a fragment thereof.
[0105] In some aspects, the analyte is an anti-PD-1 antibody. In some aspects, the anti-PD-1 antibody is selected from the group consisting of nivolumab (also known as OPDIVO®, 5C4, BMS-936558, MDX-1106, and ONO-4538), pembrolizumab (Merck; also known as KEYTRUDA®, lambrolizumab, and MK-3475; see WO 2008 / 156712), PDR001 (Novartis; see WO 2015 / 112900), MEDI-0680 (AstraZeneca; also known as AMP-514; see WO 2012 / 145493), cemiplimab (Regeneron; also known as REGN-2810; see WO 2015 / 112800), JS001 (TAIZHOU JUNSHI PHARMA; Si-Yang Liu et al., J. Hematol. Oncol. 10:136 (2017)), BGB-A317 (Beigene; see WO 2015 / 35606 and US 2015 / 0079109), INCSHR1210 (Jiangsu Hengrui Medicine; also known as SHR-1210; WO 2015 / 085847; see Si-Yang Liu et al., J. Hematol. Oncol. 10:136 (2017)), TSR-042 (Tesaro Biopharmaceutical; also known as ANB011; see WO2014 / 179664), GLS-010 (Wuxi / Harbin Gloria Pharmaceuticals; also known as WBP3055; Si-Yang Liu et al., J. Hematol. Oncol.10:136 (2017)), AM-0001 (Armo), STI-1110 (Sorrento Therapeutics; see WO 2014 / 194302), AGEN2034 (Agenus; see WO 2017 / 040790), MGA012 (Macrogenics, see WO 2017 / 19846), and IBI308 (Innovent; see WO 2017 / 024465, WO 2017 / 025016, WO 2017 / 132825, and WO 2017 / 133540).
[0106] In some aspects, the analyte is an anti-PD-L1 antibody. In some aspects, the anti-PD-L1 antibody is an antibody such as BMS-936559 (12A4, also known as MDX-1105; e.g., U.S. Patent No. 7,943,743 and WO 2013 / 173223), atezolizumab (Roche; TECENTRIQ®; also known as MPDL3280A, RG7446; see U.S. Patent No. 8,217,149; see also Herbst et al. (2013) J Clin Oncol 31(suppl):3000), durvalumab (AstraZeneca; IMFINZI®, also known as MEDI-4736; see WO 2011 / 066389), avelumab (Pfizer; BAVENCIO®, also known as MSB-0010718C; see WO 2013 / 079174), STI-1014 (Sorrento; see WO 2013 / 181634), CX-072 (Cytomx; see WO 2016 / 149201), KN035 (3D Med / Alfamab; see Zhang et al., Cell Discov. 7:3 (March 2017), LY3300054 (Eli Lilly Co.; see, e.g., WO 2017 / 034916), and CK-301 (Checkpoint Therapeutics; see Gorelik et al., AACR:Abstract 4606 (Apr 2016)).
[0107] In some aspects, the analyte is CD73 or a portion thereof. In some aspects, the SIL analyte is V[Ile( 13 C 6 , 15 N)]YPAVEGR (SEQ ID NO: 1). In some aspects, the analyte is PD-1 or a portion thereof. In some aspects, the SIL analyte is LAAFPED[Arg( 13 C 6 , 15 N 4 )] (SEQ ID NO:2). In some aspects, the analyte is PD-L1 or a portion thereof. In some aspects, the SIL analyte is LQDAG[Val( 13 C 5 , 15 N)]YR (SEQ ID NO:3). In some aspects, the analyte is daclatasvir. In some aspects, the SIL analyte is 13 C 2 15 N 4 -Daclatasvir.
[0108] In some aspects, the analyte is a non-peptide molecule. In some aspects, the analyte has a molecular weight of at least 100 g / mol, at least 200 g / mol, at least 300 g / mol, at least 400 g / mol, at least 500 g / mol, at least 600 g / mol, at least 700 g / mol, at least 800 g / mol, at least 900 g / mol, at least 1000 g / mol, at least 1100 g / mol, at least 1200 g / mol, at least 1300 g / mol, at least 1400 g / mol, at least 1500 g / mol, at least 1600 g / mol, at least 1700 g / mol, at least 1800 g / mol, at least 1900 g / mol, or at least 2000 g / mol.
[0109] In some aspects, the analyte is an antibacterial or antiviral agent. In some aspects, the analyte is an agent against hepatitis B, hepatitis C, HIV, syphilis, or any combination thereof. In another aspect, the analyte having anti-HCV activity is useful for inhibiting the function of a target selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV association, HCV egress, HCV NS5A protein, and IMPDH, and / or cyclosporine analogs, and / or nucleoside analogs for the treatment of HCV or flavivirus infection.
[0110] Among the analytes that can be used in the present disclosure as selective HCV serine protease inhibitors are those disclosed in patents WO / 1999 / 007733, WO / 2005 / 007681, WO / 2005 / 028502, WO / 2005 / 035525, WO / 2005 / 037860, WO / 2005 / 077969, WO / 2006 / 039488, WO / 2007 / 0 22459, WO / 2008 / 106058, WO2008 / 106139, WO / 2000 / 009558, WO / 2000 / 009543, WO / 1999 / 064442, WO / 1999 / 007733, WO / 1999 / 07734, WO / 1999 / 050230, and WO / 1998 / 017679. NS5B polymerase inhibitors have also shown activity. These agents include, but are not limited to, other inhibitors of HCV RNA-dependent RNA polymerase, such as nucleoside-type polymerase inhibitors, e.g., those described in WO01 / 90121(A2), U.S. Pat. No. 6,348,587B1, or WO01 / 60315, or WO01 / 32153, or non-nucleoside inhibitors, such as the benzimidazole polymerase inhibitors described in EP162196A1 or WO02 / 04425.
[0111] In addition to the combination of PEGylated alpha-interferon and ribavirin, other combinations of compounds useful for treating HCV-infected patients that selectively inhibit HCV viral replication are desired.In particular, combinations of agents that are effective in inhibiting the function of NS5A protein with agents that are effective in inhibiting other viral targets are desired.HCV NS5A protein is described, for example, in Tan, S.-L.; Katzel, MG Virology (2001) 284, 1-12, and Park, K.-J.; Choi, S.-H, J. Biological Chemistry (2003).HCV Relevant patent disclosures describing the synthesis of NS5A inhibitors are as follows: US2009 / 0202478; US2009 / 0202483; WO2009 / 020828; WO2009 / 020825; WO2009 / 102318; WO2009 / 102325; WO2009 / 102694; WO2008 / 144380; WO2008 / 021927; WO2008 / 021928; WO2008 / 021936; WO2006 / 133326; WO2004 / 014852; WO2008 / 070447;WO2009 / 034390;WO2006 / 079833;WO2007 / 031791;WO2007 / 070556;WO2007 / 070600;WO2008 / 064218;WO2008 / 154601;WO2007 / 082554;WO2008 / 048589;WO2010 / 017401;WO2010 / 065668;WO2010 / 065674;WO2010 / 065681, the contents of each of which are expressly incorporated by reference into this specification.
[0112] In some aspects, the analyte is a small molecule. In some aspects, the analyte is taxol, clopidogrel, apixaban, dapagliflozin, saxagliptin, temsavir, ledipasvir, sofosbuvir, or rosuvastatin. In some aspects, the analyte is taxol. In some aspects, the analyte is clopidogrel. In some aspects, the analyte is apixaban. In some aspects, the analyte is dapagliflozin. In some aspects, the analyte is saxagliptin. In some aspects, the analyte is temsavir. In some aspects, the analyte is ledipasvir. In some aspects, the analyte is sofosbuvir. In some aspects, the analyte is rosuvastatin.
[0113] In another aspect, the analyte is a nucleic acid molecule, eg, DNA, RNA, eg, mRNA. In some aspects, the nucleic acid molecules are at least about 10 nucleic acids, at least about 15 nucleic acids, at least about 20 nucleic acids, at least about 25 nucleic acids, at least about 30 nucleic acids, at least about 40 nucleic acids, at least about 50 nucleic acids, at least about 100 nucleic acids, at least about 200 nucleic acids, at least about 300 nucleic acids, at least about 400 nucleic acids, at least about 500 nucleic acids, at least about 600 nucleic acids, at least about 700 nucleic acids, at least about 800 nucleic acids, at least about 900 nucleic acids, at least about 1000 nucleic acids, at least about 1200 nucleic acids, at least about 1400 nucleic acids, at least about 1600 nucleic acids, at least about 1800 nucleic acids, at least about 2000 nucleic acids, at least about 2200 nucleic acids, at least about 2400 nucleic acids, at least about 2600 nucleic acids, at least about 2800 nucleic acids, or at least about 3000 nucleic acids.
[0114] In some aspects, the analyte is an antisense oligonucleotide. In other aspects, the analyte is an siRNA or miRNA. In other aspects, the analyte is a gene therapy vector or a plasmid.
[0115] In some aspects, the SIL analyte comprises at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20 isotopic labels, at least about 21, at least about 22, at least about 23, at least about 24, at least about 25, at least about 26, at least about 27, at least about 28, at least about 29, at least about 30, at least about 31, at least about 32, at least about 33, at least about 34, at least about 35, at least about 36, at least about 37, at least about 38, at least about 39, or at least about 40 isotopic labels.
[0116] The selection of the MIRM transitions for measurement is a critical element of the disclosed methods to ensure stable and accurate assay performance. In some aspects, each of the measured relative peak areas at the MIRM transitions has a deviation of less than 15% from the theoretical isotopic abundance calculated at the corresponding MIRM transition of the SIL analyte or the naturally occurring isotopic species of the SIL analyte.
[0117] In some aspects, at least one of the measured relative peak areas for the MIRM transitions is less than 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 0.9%, 0.8 ... a deviation of less than 0.1%, less than 0.09%, less than 0.08%, less than 0.07%, less than 0.06%, less than 0.05%, less than 0.04%, less than 0.03%, less than 0.02%, less than 0.01%, less than 0.009%, less than 0.008%, less than 0.007%, less than 0.006%, less than 0.005%, less than 0.004%, less than 0.003%, less than 0.002%, less than 0.001%, less than 0.009%, less than 0.008%, less than 0.007%, less than 0.006%, less than 0.005%, less than 0.004%, less than 0.003%, less than 0.002%, or less than 0.0001%. In some aspects, all of the measured relative peak areas at the MIRM transitions have a deviation of less than 14% from the calculated theoretical isotopic abundance at the corresponding MIRM transitions of the SIL analyte, or of a naturally occurring isotopic species of the SIL analyte. In some aspects, all of the measured relative peak areas at the MIRM transitions have a deviation of less than 13% from the calculated theoretical isotopic abundance at the corresponding MIRM transitions of the SIL analyte, or of a naturally occurring isotopic species of the SIL analyte. In some aspects, all of the measured relative peak areas at the MIRM transitions have a deviation of less than 12% from the calculated theoretical isotopic abundance at the corresponding MIRM transitions of the SIL analyte, or of a naturally occurring isotopic species of the SIL analyte. In some aspects, all of the measured relative peak areas at the MIRM transitions have a deviation of less than 11% from the calculated theoretical isotope abundances at the corresponding MIRM transitions of the SIL analyte or naturally occurring isotopic species of the SIL analyte.In some aspects, all of the measured relative peak areas at the MIRM transitions have less than a 10% deviation from the calculated theoretical isotopic abundance at the corresponding MIRM transitions of the SIL analyte or naturally occurring isotopic species of the SIL analyte. In some aspects, all of the measured relative peak areas at the MIRM transitions have less than a 9% deviation from the calculated theoretical isotopic abundance at the corresponding MIRM transitions of the SIL analyte or naturally occurring isotopic species of the SIL analyte. In some aspects, all of the measured relative peak areas at the MIRM transitions have less than an 8% deviation from the calculated theoretical isotopic abundance at the corresponding MIRM transitions of the SIL analyte or naturally occurring isotopic species of the SIL analyte. In some aspects, all of the measured relative peak areas at the MIRM transitions have less than a 7% deviation from the calculated theoretical isotopic abundance at the corresponding MIRM transitions of the SIL analyte or naturally occurring isotopic species of the SIL analyte.
[0118] In some aspects, the number of MIRM transitions is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20. In some aspects, the number of MIRM transitions is between 4 and 15, between 4 and 14, between 5 and 13, between 5 and 12, between 6 and 12, between 6 and 11, between 7 and 11, between 7 and 10, between 8 and 10, or between 8 and 9. In some aspects, the number of MIRM transitions is between 4 and 10, between 4 and 9, between 5 and 9, between 6 and 9, between 6 and 8, or between 7 and 8. In some aspects, the number of MIRM transitions is 6. In some aspects, the number of MIRM transitions is 7. In some aspects, the number of MIRM transitions is 10. In some aspects, the number of MIRM transitions is 15.
[0119] In some aspects, the analyte concentration equivalents of the largest MIRM channel and the smallest MIRM channel are at least about 10 fold, at least about 100 fold, at least about 200 fold, at least about 300 fold, at least about 400 fold, at least about 500 fold, at least about 600 fold, at least about 700 fold, at least about 800 fold, at least about 900 fold, at least about 1000 fold, at least about 1100 fold, at least about 1200 fold, at least about 1300 fold, at least about 1400 fold, at least about 1500 fold, at least about 1600 fold, at least about 1700 fold, at least about 1800 fold, at least about 1900 fold, at least about 2000 fold, at least about 2100 fold, at least about 2200 fold, at least about 2300 fold, at least about 2400 fold, at least about 2500 fold, at least about 2600 fold, at least about 2700 fold, at least about 2800 fold, at least about 2900 fold, at least about 3000 fold, at least about 3100 fold, at least about 3200 fold, at least about 3300 fold, at least about 3400 fold, at least about 3500 fold, at least about 3600 fold, at least about 3700 fold, at least about 3800 fold, at least about 3900 fold, at least about 4000 fold, at least about 4100 fold, at least about 4200 fold, at least about 4300 fold, at least about 4400 fold, at at least about 2900 times, at least about 3000 times, at least about 3100 times, at least about 3200 times, at least about 3300 times, at least about 3400 times, at least about 3500 times, at least about 3600 times, at least about 3700 times, at least about 3800 times, at least about 3900 times, at least about 4000 times, at least about 4100 times, at least about 4200 times, at least about 4300 times, at least about 4400 times, at least about or by at least about 4500 fold, at least about 4600 fold, at least about 4700 fold, at least about 4800 fold, at least about 4900 fold, at least about 5000 fold, at least about 5100 fold, at least about 5200 fold, at least about 5300 fold, at least about 5400 fold, at least about 5500 fold, at least about 5600 fold, at least about 5700 fold, at least about 5800 fold, at least about 5900 fold, or at least about 6000 fold.
[0120] In some aspects, the calculated theoretical isotopic abundances of two selected MIRM transitions are at least 0.01%, at least 0.05%, at least 0.1%, at least 0.5%, at least 1%, at least 1.5%, at least 2%, at least 2.5%, at least 3%, at least 3.5%, at least 4%, at least 4.5%, at least 5%, at least 5.5%, at least 6%, at least 6.5%, at least 7%, at least 7.5%, at least 8%, at least 8.5%, at least 9%, at least 9.5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least about 50% apart.
[0121] In some aspects, the SIL analyte contains trace amounts of unlabeled analyte, ie, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.9%, less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, or less than 0.1% of unlabeled analyte.
[0122] In some aspects, the SIL analyte is labeled at one or more sites with one or more stable isotopes. In some aspects, the stable isotope label is 2 H, 13 C. 15 N, 33 S, 34 S, 36 S, 17 O, or 18 In some aspects, the stable isotope label is 13 C and / or 15 In some aspects, the stable isotope label is 13 C. In some aspects, the stable isotope label is 15 It's N.
[0123] Typically, for an experiment in a triple quadrupole mass spectrometer, the first quadrupole (Q1) is configured to pass only ions of a particular m / z (precursor ions) of the expected species in the sample. The second quadrupole (i.e., Q2 or collision cell) is used to fragment the ions that pass through Q1. The third quadrupole (Q3) is configured to pass only ions of a particular m / z (fragment ions) that correspond to the expected fragmentation products of the expected species to the detector. In some aspects, the sample is ionized in the mass spectrometer to produce one or more protonated or deprotonated molecular ions. In some aspects, the one or more protonated or deprotonated molecules are singly, doubly, triply, or more charged. In some aspects, the mass spectrometer is a triple quadrupole mass spectrometer. In some aspects, the resolution used for Q1 and Q3 is unit resolution. In other aspects, the resolution used for Q1 and Q3 is different. In another aspect, the resolution used for Q1 is higher than the unit resolution used for Q3.
[0124] The usefulness of high performance liquid chromatographic separation has been demonstrated for a wide range of applications, such as the analysis and purification of molecules ranging from low to high molecular weight. In liquid chromatography, there is a major limitation, especially arising from the time required for analysis. The method of the present disclosure is highly effective and improves the total instrument time required, especially in cases where an external calibration curve does not need to be run on the instrument. In some aspects, the method reduces the total instrument run time. In some aspects, no external calibration curve is used. In some aspects, the analyte is a biomarker. In some aspects, the analyte is a metabolite.
[0125] The disclosed method is effective for detecting or quantifying analytes from various sources, such as biological sources. In some aspects, the sample is serum, tissue, biopsy tissue, formalin-fixed / paraffin-embedded (FFPE), plasma, saliva, cerebrospinal fluid, tears, urine, synovial fluid, dried blood spot, or any combination thereof. In some aspects, the sample is serum. In some aspects, the sample is tissue. In some aspects, the sample is biopsy tissue. In some aspects, the sample is formalin-fixed / paraffin-embedded (FFPE). In some aspects, the sample is plasma. In some aspects, the sample is saliva. In some aspects, the sample is cerebrospinal fluid. In some aspects, the sample is tears. In some aspects, the sample is urine. In some aspects, the sample is synovial fluid. In some aspects, the sample is a dried blood spot.
[0126] The disclosed methods are also useful for constructing liquid chromatography-mass spectrometry systems, including liquid chromatography, that include at least one liquid chromatography column capable of separating an analyte from a biological matrix, a sample containing the analyte of interest, at least one stable isotope-labeled analyte added to the sample, and a mass spectrometer capable of ionizing, fragmenting, and detecting one or more protonated or deprotonated parent ions, daughter ions specific to the analyte, and the stable isotope-labeled analyte. In general, chromatography is any type of technique that separates a molecule (e.g., an antibody) from other molecules (e.g., contaminants) present in a mixture.
[0127] Liquid chromatography (LC) is a well-established analytical technique for separating components of a fluid mixture for subsequent analysis and / or identification, in which a column, microfluidic chip-based channel, or tube is packed with a stationary phase material, which is generally a finely ground solid or gel, such as small particles of a few microns in diameter. The small particle size provides a large surface area that can be modified by various chemicals to produce the stationary phase. A liquid eluent is delivered to the liquid chromatography column ("LC column") at a desired flow rate based on the column dimensions and particle size. This liquid eluent is sometimes referred to as the mobile phase. The sample to be analyzed is introduced (e.g., injected) in small amounts into the mobile phase stream prior to the LC column. The migration rate of the analytes in the sample is influenced by specific chemical and / or physical interactions of the stationary phase as it traverses the length of the column. The time at which a particular analyte elutes or emerges from the end of the column is called the retention time or elution time, and can reasonably identify the characteristics of a particular analyte, especially when combined with other analytical characteristics, such as the exact molecular weight of the particular analyte. The separated components may be sent from the liquid chromatography column to other types of analytical instruments for further analysis, for example, liquid chromatography-mass spectrometry (LC / MS or LC / MS / MS), which chromatographically separates compounds before they are introduced into the ion source of a mass spectrometer.
[0128] Mass spectrometry ("MS" or "mass spectrometry") is an analytical technique used to measure mass-to-charge ratio ions. This is accomplished by ionizing a sample, separating ions of different masses, and recording their relative abundance by measuring the intensity of the ion flow. A typical mass spectrometer includes three parts: an ion source, a mass analyzer, and a detection system. The ion source is the part of the mass spectrometer that ionizes the substances to be analyzed (analytes). The ions are then delivered by a magnetic or electric field to the mass analyzer, where the ions are separated according to their mass-to-charge ratio (m / z). Many mass spectrometers use two or more mass analyzers for tandem mass spectrometry (MS / MS). The detector records the charge induced, or the current generated, when the ions pass through or impact a surface. Mass spectrometry is the result of measuring the signal produced at the detector as the m / z ions are scanned by the mass spectrometer.
[0129] The disclosed method discloses a composition comprising an Intra-Sample Calibration Curve (ISCC), where the ISCC comprises a Multi-Isotopic Species Reaction Monitoring (MIRM) of a stable isotope-labeled analyte. The disclosed method of generating an ISCC comprising a MIRM of a stable isotope-labeled analyte is useful for the analysis of biomarkers. Biomarkers can be, for example, isolated from a biological sample, directly measured in a biological sample, or detected or determined to be in a biological sample. Biomarkers can be functional, partially functional, or non-functional. If the biomarker is a protein or a fragment thereof, it can be sequenced and its encoding gene can be cloned using well-established techniques. The disclosed method is also useful for the development and / or validation of biomarkers for regulatory approval as surrogate endpoints. Surrogate endpoints are biomarkers approved by regulatory agencies as a surrogate for a clinical endpoint and are intended to be used as a surrogate for a clinically meaningful endpoint. Before a surrogate endpoint can be approved, extensive evidence is required that it can be reliably predicted or associated with clinical benefit.
[0130] The disclosed method is also useful for the analysis of biomarkers, metabolites, or metabolic profiles. The analysis of biomarkers or metabolites shows a highly accurate measure of the biological state of health or disease. The altered metabolic fingerprint, unique to each individual, provides new means to further understand systems biology, detect or identify potential risks of various diseases, and ultimately help achieve the goal of personalized medicine (i.e., the right drug, at the right dose, at the right time, to the right person). A metabolite profile as used in the present invention should be understood to be any defined value list of quantitative results of metabolites that can be used to compare with reference values or profiles obtained from another sample or group of samples. For example, the metabolite profile of a sample from a patient with a disease may be significantly different from the metabolite profile of a sample from a similarly matched healthy patient. The metabolite profile may help predict the patient's susceptibility to a disorder by comparing the profile to a reference or standard profile.
[0131] The disclosed method also relates to recommending or selecting the optimal treatment protocol and / or optimal drug selection, combination, and dosage for a particular patient. The peak concentration of the drug after each administration can be measured. The trough concentration of the drug after each administration can also be measured. The administration interval (time), including the variation therebetween, can be optimized based on information determined from the analysis of biomarkers or metabolites.
[0132] The present disclosure also includes liquid chromatography-mass spectrometry systems used with the methods described herein. In some aspects, the LC-MS / MS comprises: (i) liquid chromatography, comprising at least one liquid chromatography column capable of separating an analyte from a biological matrix; (ii) a sample containing the analyte of interest; (iii) at least one stable isotope-labeled analyte added to the sample; and (iv) a mass spectrometer capable of ionizing, fragmenting, and detecting one or more protonated (or deprotonated) parent and daughter ions specific to the analyte and the stable isotope-labeled analyte. Includes.
[0133] In another aspect, the disclosure includes a composition comprising an intra-sample calibration curve (ISCC), where the ISCC comprises a stable isotope labeled analyte.
[0134] The present disclosure also relates to the creation of a one-sample multi-point external calibration curve (OSMECC). This approach does not use a stable labeled isotope (SIL) analyte, but instead involves spiking a known amount of the analyte into a blank matrix sample. A blank matrix is a type of matrix that does not contain the analyte of interest. By spiking a known amount of the analyte into one blank matrix sample, a one-sample multi-point external calibration curve of the blank matrix sample can be established based on the relationship between the calculated theoretical isotope abundance (analyte concentration equivalent) and the measured MS / MS peak area (or peak area ratio if an internal standard is used in the assay) in the corresponding MIRM channel of the analyte. This one-sample multi-point external calibration curve can be used in the same manner as a conventional multi-sample external calibration curve for quantitative LC-MS / MS-based bioanalysis. This approach serves as an alternative method for LC-MS / MS quantitative analysis without the need to create a conventional multi-sample external calibration curve.
[0135] Since the isotope abundance in each MIRM channel can be accurately calculated and measured, isotopic sample dilution can be achieved by simply tracking the MIRM channel of one or a few analytes in addition to the most abundant MIRM channel of the test sample. The most abundant MIRM channel (100% isotope abundance) is used to quantify samples with concentrations within the assay calibration curve range, while the less abundant MIRM channel (IA% isotope abundance) can be used to quantify samples with concentrations above the upper limit of quantification (ULOQ) of the assay, resulting in an isotope dilution factor (IDF) of 100% / IA%. This approach serves as an alternative method to eliminate the need to physically dilute test samples in LC-MS / MS quantitative analysis.
[0136] In some aspects, the disclosure relates to a method of quantifying the concentration of at least one analyte in a research sample, the method comprising spiking one or more known amounts of one or more analytes into a blank matrix sample and constructing one or more single sample multi-point external calibration curves (OSMECC) by multiple isotopic species reaction monitoring (MIRM) of each spiked analyte, where MIRM of an analyte refers to multiple reaction monitoring of multiple isotopic transitions of the analyte; where the OSMECC of each analyte is calculated based on the theoretical isotopic abundance (analyte concentration equivalent) calculated at the MIRM transition and the isotopic abundance (analyte concentration equivalent) calculated at the corresponding MIRM transition. A relationship between the measured tandem mass spectrometry (MS / MS) peak area (or peak area ratio, if an internal standard is used in the assay) and the concentration of at least one analyte in the study sample is quantified using an established OSMECC and the measured peak area (or peak area ratio, if an internal standard is used in the assay) for the analyte from a liquid chromatography-tandem mass spectrometry (LC-MS / MS) process; where the peak area ratio for the analyte is the peak area of the analyte divided by the peak area of the internal standard, where the tandem mass spectrometer is operated in multiple reaction monitoring.
[0137] The present disclosure is further illustrated by the following examples, which should not be construed as further limiting. The contents of all references cited throughout this application are expressly incorporated herein by reference. EXAMPLES
[0138] Example 1 Preparation of SIL analytes for MIRM-ISCC-LC-MS / MS analysis Formic acid (SupraPur grade) was purchased from EMD Chemicals (Gibbstown, NJ, USA). HPLC grade methanol and acetonitrile were purchased from JT Baker (Phillipsburg, NJ, USA). LC grade ammonium bicarbonate and phosphate buffered saline with 0.05% tween (PBST) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Dynabeads® M-280 streptavidin was purchased from Invitrogen (Carlsbad, CA, USA). Sequencing grade modified trypsin was purchased from Promega Corporation (Madison, WI, USA). All unlabeled and labeled surrogate peptides of cluster of differentiation 73 (CD73): VIYPAVEGR (SEQ ID NO: 1) and V[Ile( 13 C 6 , 15 N)]YPAVEGR (SEQ ID NO: 1); programmed cell death protein 1 (PD-1): LAAFPEDR (SEQ ID NO: 2) and LAAFPED [Arg( 13 C 6 , 15 N 4 )] (SEQ ID NO: 2); and programmed cell death ligand 1 (PD-L1): LQDAGVYR (SEQ ID NO: 3) and LQDAG[Val( 13 C 5 , 15N)]YR (SEQ ID NO:3) was purchased from Genscript (Piscataway, NJ, USA). Deionized water was generated using a NANOpure Diamond ultrapure water system from Barnstead International (Dubuque, IA, USA). Recombinant human CD73 (61,084 Da), anti-human CD73 monoclonal antibody (mAb), small molecule drug daclatasvir, and SIL drug, 13 C 2 15 N 4 -Daclatasvir was created.
[0139] The LC-MS / MS system used was a triple quadrupole 6500 mass spectrometer (AB Sciex, Foster City, CA) coupled to a Nexera UPLC system (Shimadzu, Columbia, MD). The UPLC system consisted of two LC-30AD pumps, one SIL-30ACMP autosampler, and one CTO-30AS column heater. Separation was performed on an Acquity HSS T3 analytical column (2.1 mm x 50 mm, 1.8 μm particle size) (Waters, Milford, MA) by gradient elution with a mobile phase of 0.01% formic acid / water (A) and 0.01% formic acid / acetonitrile (B). LC-MS / MS data were acquired with Analyst® Software (1.6.2).
[0140] Selection of MIRM channels for tracking FIG. 1 illustrates a general MIRM-ISCC-LC-MS / MS method using the quantitative analysis of the programmed death-ligand 1 (PD-L1) peptide LQDAGVYR (SEQ ID NO: 3) as an example. Each 100 μL study sample contained a known amount of the SIL analyte LQDAG[Val( 13 C 5 , 15By spiking 20 μL of 500 ng / mL=10 ng) of 100 μL ...
[0141] MIRM-ISCC-LC-MS / MS quantification of endogenous CD73 in human and monkey serum CD73 is a 70 kDa protein that shows high expression in many tumors. Quantitative analysis of CD73 in human and monkey serum is necessary to aid in dose selection and provide pharmacodynamic information for anti-CD73 preclinical and clinical drug development. Initially, we developed and validated an immunocapture LC-MS / MS assay with a conventional external calibration curve by serial dilutions of a recombinant CD73 reference standard (61,084 Da) in a surrogate matrix. Anti-CD73 mAb was used for immunocapture of CD73, followed by denaturation, trypsin digestion, and LC-MS / MS analysis. The surrogate peptides monitored in the LC-MS / MS assay (unique to both human and monkey CD73) were converted from the doubly charged parent ion to the y6 ion (502.3 ++ →628.3 + The SIL surrogate peptide, V[Ile( 13 C 6 , 15N)]YPAVEGR (SEQ ID NO:1) was added to each sample after trypsin digestion at a concentration of 100 ng / mL. Since the original serum sample volume for this assay was 100 μL, this corresponds to 10 ng / mL ([10 μL·100 ng / mL] / 100 μL) of SIL peptide in the original serum sample, or 604.792 ng / mL of recombinant CD73 (10 ng / mL·[61,084 Da / 1010 Da]). In this experiment, this labeled peptide was used not only as an internal standard for the assay along with an external calibration curve, but also as the ISCC for each individual study sample. This allows a side-by-side comparison of CD73 concentrations measured by the external calibration curve and the ISCC.
[0142] Before quantification of CD73 in human and monkey serum using an external calibration curve and ISCC approach, a labeled surrogate peptide, V[Ile( 13 C 6 , 15 The isotope abundances in the MIRM channels for N)]YPAVEGR (SEQ ID NO:1) should be calculated and measured to ensure that the selected MIRM channels are reliable and accurate for establishing ISCC without unexpected interference.
[0143] Fragmentation of peptides in triple quadrupole mass spectrometers can be easily resolved by using online tools such as Skyline (MacCoss Lab, Department of Genome Sciences, UW). In this case, the y6 ion is monitored as a daughter ion, so the daughter ion and neutral loss are C 26 H 46 N 9 O 9 + and 13 C 6 15 NC 14 H 29 N 2 O 4 The daughter ion (C 26 H 46N 9 O 9 + ) and neutral loss ( 13 C 6 15 NC 14 H 29 N 2 O 4 The isotope distribution of V[Ile( 13 C 6 , 15 The isotopic abundances in the most abundant MIRM channel (100% abundance) and adjacent MIRM channels for V[ILE( 13 C 6 , 15 The calculated theoretical isotope abundances and measured results (peak areas) for N)]YPAVEGR (SEQ ID NO:1) in the corresponding MIRM channels using a Sciex API 6500 mass spectrometer are shown in Table 2. The abundances range more than 6,000-fold from the most abundant to the least abundant MIRM channels. Lower isotope abundances can also be calculated and used if necessary, but in many cases will exceed the linear range of the triple quadrupole mass spectrometer. As shown in Table 2, the difference in the percentage of the measured results from the calculated theoretical isotope abundances is within 13.5%, indicating that the measurement results are accurate and reliable without any interference, such as isotopic impurities and interference from endogenous matrix, and therefore these MIRM channels can be selected for MIRM-ISCC-LC-MS / MS absolute quantitative analysis.
[0144] Using the calculated theoretical isotope abundances in the MIRM channels for the SIL peptides, the spiked SIL peptide isotope concentrations (and CD73 protein concentration equivalents) in the 10 selected MIRM channels used for ISCC were calculated and listed in the right two columns of Table 2. ISCCs are constructed in each study sample using these concentrations (x-axis) and the measured MS / MS peak areas in the corresponding MIRM channels (y-axis). Calibration curve regression and concentration calculations were performed using in-house developed software. Weighting (1 / x 2 ) Linear least squares regression was used for all ISCCs. ISCC performance, linear curves (intercept and linear slope) and calculated concentrations for the first three injections for sample number 1 in human plasma are shown in Tables 3 and 4, respectively (all samples were extracted and analyzed in triplicate). Excellent ISCC performance was observed for these three replicates, as shown in Table 3. Representative chromatograms for the 10 MIRM channels used for ISCC and one SRM channel for the second injection are shown in Figures 2A and 2B.
[0145] The results of quantitative analysis of endogenous CD73 amounts in human and monkey serum using external calibration curves and ISCC approach are listed in Table 5. Overall, CD73 concentrations measured by ISCC approach are about 11% to 17% lower than those measured using external calibration curves. This is because the immunocapture and digestion losses of the study samples were tracked and corrected by external calibration curves, resulting in a recovery rate of 86.0% due to immunocapture and digestion. However, this was not the case for ISCC approach, since SIL peptide was spiked after digestion. Therefore, as shown in Table 5, the concentrations measured by ISCC approach should be corrected by the recovery rate of 86.0%, and the corrected concentrations were in very good agreement with those measured using external calibration curves.
[0146] It is not necessary to include all promising MIRM channels in the final assay. The MIRM channels selected for quantification of CD73 in human serum are shown in Table 2. There are several considerations when selecting the MIRM channels to be used in performing sample analysis:
[0147] The ISCC curve range is defined by the isotope abundance range of the selected MIRM channel. Therefore, appropriate MIRM channels must be selected to cover the expected concentration range. In this work, the selected MIRM channels covered the curve range of approximately 1,600-fold, covering the expected increase in CD73 after administration.
[0148] Any MIRM channel with a large %Dev (>15%) between the calculated and measured isotope abundances should not be selected because a large %Dev usually indicates the presence of potential interferences in the MIRM channel, such as isotopic impurities and interference from endogenous matrix. Therefore, multiple matrix lots should be tested for the MIRM channel selection.
[0149] Among multiple MIRM channels with similar isotopic abundances, only one MIRM channel should be selected. In this example, MIRM channels 4 and 5, 7 and 8 have very similar isotopic abundances, as shown in Table 2, so MIRM channels 4 and 8 were not selected.
[0150] For demonstration purposes only, a total of 10 MIRM channels were used in this example. Using fewer MIRM channels (4-5 MIRM channels for a 1,000x curve) does not impact data quality. Table 1 Stable isotope-labeled peptide V[Ile( 13 C 6 , 15 N)]YPAVEGR (SEQ ID NO: 1) neutral loss ( 13 C 615 NC 14 H 29 N 2 O 4 ) and daughter ion ([C 26 H 46 N 9 O 9 ] + ) isotopic distribution [Table 1] Note: Parent ion: [ 13 C 6 15 NC 40 H 76 N 11 O 13 ] ++ , two-valent (Z p =2) [Table 2] a 10 μL of 100 ng / mL (1 ng) SIL peptide was spiked into the digested sample. Since the original sample volume used in the assay was 100 μL, this equates to 10 ng / mL of SIL peptide in the most abundant MIRM channel in the original sample. The other SIL peptide isotope concentrations in adjacent MIRM channels were calculated based on the calculated theoretical relative isotope abundances. b Equivalent CD73 protein concentration = SIL peptide isotope concentration * (recombinant CD73 molecular weight 61,084 / SIL peptide molecular weight 1010). [Table 3] [Table 4] [Table 5] a Percentage difference between ISCC CD73 protein concentration and external standard curve CD73 protein concentration b Because the spiked SIL peptide did not undergo the immunocapture and digestion steps, CD73 concentrations were corrected by the immunocapture and digestion recovery (86.0%). c Percentage difference between recovery-corrected CD73 protein concentration using ISCC and CD73 protein concentration using an external standard curve
[0151] Example 2 MIRM-ISCC-LC-MS / MS quantification of surrogate peptides of protein biomarkers PD-1, PD-L1, and CD73 in digested human colon homogenates The above MIRM-ISCC-LC-MS / MS method can be easily applied to quantitative proteomics by spiking known amounts of multiple SIL surrogate peptides into digested samples for absolute quantitative proteomics for multiple peptide targets. Similar to the AQUA approach, the quantification of ISCC is also based on the concentration of SIL surrogate peptides spiked into the sample. However, since only one calibration point for each target peptide is used in the AQUA approach, the accuracy of quantification may be greatly reduced, especially when the concentration of the target peptide is much higher or much lower than the concentration of the spiked SIL surrogate peptide. Meanwhile, the MIRM-ISCC-LC-MS / MS approach can provide a complete calibration curve range of 3-4 orders of magnitude for each target peptide, and the accuracy of quantification can be guaranteed throughout the calibration curve range.
[0152] In this example, three surrogate peptides, LAAFPEDR (SEQ ID NO:2) for PD-1, LQDAGVYR (SEQ ID NO:3) for PD-L1, and VIYPAVEGR (SEQ ID NO:1) for CD73, were mixed and spiked into trypsin-completely digested human colon tissue homogenate at concentrations of 1.00, 10.0, and 50.0 ng / mL, respectively. A volume of 100 μL of prepared sample was used for the assay. For MIRM-ISCC-LC-MS / MS analysis, 10 ng (20 μL of 500 ng / mL) of each SIL peptide LAAFPED[Arg( 13 C 6 , 15 N 4 )] (SEQ ID NO: 2), LQDAG[Val( 13 C 5 , 15 N)]YR (SEQ ID NO: 3), and V[Ile( 13 C 6 , 15 A mixture of N)]YPAVEGR (SEQ ID NO:1) in 10% methanol 90% water was added to the prepared samples. The concentration of each SIL peptide in the samples is 100 ng / mL (10 ng / 100 μL). Table 6 shows the MIRM channels, their isotopic concentrations, and analyte concentration equivalents used for the MIRM-ISCC-LC-MS / MS quantitative analysis of these three peptides. All ISCC curves were weighted (1 / x 2 ) using least-squares linear regression. Good ISCC performance was demonstrated by highly accurate predicted concentrations for all calibration points (within 10.0% of apparent concentrations, data not shown). The measured concentrations of these three peptides are shown in Table 7, and the accuracy of the MIRM-ISCC-LC-MS / MS measurements was confirmed by all of the samples tested. Table 6 MIRM channels and their isotope concentrations used for MIRM-ISCC-LC-MS / MS quantitative analysis of LAAFPEDR (SEQ ID NO:2), LQDAGVYR (SEQ ID NO:3), and VIYPAVEGR (SEQ ID NO:1) in digested human colon homogenates. [Table 6] a ISCC LAAFPEDR (SEQ ID NO: 2) concentration equivalent = ISCC SIL-LAAFPEDR (SEQ ID NO: 2) isotope concentration * (LAAFPEDR (SEQ ID NO: 2) molecular weight 918 / SIL-LAAFPEDR (SEQ ID NO: 2) molecular weight 928) b ISCC LQDAGVYR (SEQ ID NO: 3) concentration equivalent = ISCC SIL-LQDAGVYR (SEQ ID NO: 3) isotope concentration * (LQDAGVYR (SEQ ID NO: 3) molecular weight 921 / SIL-LQDAGVYR (SEQ ID NO: 3) molecular weight 927) c ISCC VIYPAVEGR (SEQ ID NO: 1) concentration equivalent = ISCC SIL-VIYPAVEGR (SEQ ID NO: 1) isotope concentration * (VIYPAVEGR (SEQ ID NO: 1) molecular weight 1003 / SIL-VIYPAVEGR (SEQ ID NO: 1) molecular weight 1010) Table 7. Quantitative analysis of the alternative peptides LAAFPEDR (SEQ ID NO:2), LQDAGVYR (SEQ ID NO:3), and VIYPAVEGR (SEQ ID NO:1) in fully digested colon tissue homogenates using MIRM-ISCC-LC-MS / MS. [Table 7]
[0153] One potential problem with the MIRM-ISCC-LC-MS / MS approach in targeted quantitative proteomics of multiple peptides is that the total number of MIRM channels that need to be monitored in an LC-MS / MS run may be too large to be handled by a triple quadrupole mass spectrometer. This problem could be mitigated by using fewer MIRM channels in each ISCC with MIRMs scheduled based on different retention time windows of each target peptide. Results showed that accurate and reliable quantification could also be achieved by using 3-4 MIRM channels in a multiplexed format for a concentration range of 2-3 orders of magnitude.
[0154] Example 3 MIRM-ICSS-LC-MS / MS Analysis of the Small Molecule Drug Daclatasvir in Human and Rat Plasma After the daughter ions and neutral losses are determined, the same MIRM-ISCC-LC-MS / MS workflow can also be used for the measurement of small molecule analytes such as small molecule drugs and biomarkers. Here, we provide an example of the real-time quantitative analysis of a small molecule drug, daclatasvir, in human and rat plasma using the MIRM-ISCC-LC-MS / MS approach.
[0155] 100 μL of human and rat plasma samples were diluted with 10, 100, 500, and 1,000 ng / mL daclatasvir and 20 μL of 5,000 ng / mL SIL in human and rat plasma, respectively. 13 C 2 15 N 4 - mixed with daclatasvir. In human and rat plasma samples 13 C 2 15 N 4-The equivalent concentration of daclatasvir was 1,000ng / mL ([20μLx5,000ng / mL] / 100μL=1,000ng / mL). Samples were extracted by liquid-liquid extraction (H. Jiang et al, Journal of Chromatography A 2012, 1245, 117-121) and injected into the MIRM-ISCC-LC-MS / MS analysis. Table 8 shows the MIRM channels and their isotope concentrations used in the ISCC for quantification of daclatasvir. All ISCCs were weighted (1 / x 2 ) were constructed using least-squares linear regression. The predicted concentrations for all calibration points are well within the regulated LC-MS / MS bioanalysis acceptance criteria (data not shown). Table 9 shows the results of the measurement of daclatasvir in human and rat plasma, indicating that the MIRM-ISCC-LC-MS / MS analysis of daclatasvir was accurate. Table 8. MIRM channels and their isotope concentrations used in the MIRM-ISCC-LC-MS / MS quantitative analysis of daclatasvir. [Table 8] a : ISCC Daclatasvir concentration equivalent = ISCC SIL-Daclatasvir isotope concentration * (Daclatasvir molecular weight 739 / SIL-Daclatasvir molecular weight 745) Table 9. Quantitative analysis of daclatasvir in human and rat plasma using MIRM-ISCC-LC-MS / MS. [Table 9]
[0156] Further considerations for the MIRM-ISCC-LC-MS / MS assay There are several further considerations for successful MIRM-ISCC-LC-MS / MS assay development and sample analysis. Selection of the appropriate SIL analyte is one of the key factors in the development of a reliable and stable quantitative MIRM-ISCC-LC-MS / MS assay. The isotopic abundance of this labeled analyte in the selected MIRM channel is used as a calibration curve for the quantitative analysis of the analyte, so the labeled analyte must be designed to avoid isotopic interference from the analyte, which may impair the accuracy of the assay. As a rule of thumb, for most small molecule compounds and peptide analytes containing 6-12 amino acids, 4-6 labels are needed to avoid interference. For the ISCC approach, a large amount of SIL analyte is needed in each study sample to define the upper limit of quantification (ULOQ) of the assay, so the impurities (amount of unlabeled analyte) of the SIL analyte must be low enough to avoid interference from the SIL analyte to the analyte. Additionally, labeled impurities (amounts of labeled analytes with fewer or more labeling sites than the SIL analytes) must also be low enough to avoid interference with the isotope abundances in the MIRM channel of the SIL analytes.
[0157] Although deuterium labeling is very cost-effective and readily available, deuterium-labeled analytes should be avoided in ISCC approaches because they are easily separated from unlabeled analytes and, more importantly, hydrogen-deuterium exchange reactions easily result in the exchange of protons and deuterons, making accurate calculation of isotope abundances in the MIRM channel impossible.
[0158] The use of a properly calibrated triple quadrupole mass spectrometer is another factor for the success of the MIRM-ISCC-LC-MS / MS approach. For singly and doubly charged parent ions, unit resolution (full width at half height-FWHH=0.7 mass units) for both Q1 and Q3 is good enough to generate accurate MS / MS responses that are close to the theoretical isotope abundances calculated in the corresponding MIRM channels. If necessary, a higher resolution in Q1 (FWHH=0.5 mass units) can improve the measurement accuracy, but at the cost of some loss of instrument sensitivity. Our test results showed that using a higher resolution in Q3 (FWHH=0.5 mass units) does not help to improve the measurement accuracy.
[0159] Since the isotope spacing (1 Da for Zp=1, 0.5 Da for Zp=2, 0.33 Da for Zp=3, etc.) gradually decreases with increasing charge number (Zp), accurate measurement of isotope abundances in MIRM channels with triply (or more) charged parent ions requires a minimum of 100 ms FWHH. < It is expected that even with a resolution of 0.5 mass units, it would be difficult. In this work, isotope abundances in MIRM channels with triply (or more) charged parent ions were not tested, since triply (or more) charged parent ions with high MS / MS response were not available.
[0160] Since ISCCs are constructed with naturally occurring isotope abundances in the selected MIRM channels without human and instrumental manipulation, the performance of the established ISCCs should be very similar between samples during assay qualification and sample analysis. For some samples, any significant unpredicted bias in one MIRM channel usually indicates endogenous interference from these matrix lots, and excluding this point does not significantly affect the accuracy of the data. On the other hand, for many samples, any significant unpredicted bias in most MIRM channels indicates a failure to calibrate the MS instrument.
[0161] Since ISCC is present in each study sample, and therefore after spiking the study sample with the SIL analyte, all variables, such as those from extraction, injection, ionization, fragmentation, and detection, are tracked and corrected by the ISCC itself, there is no need to add an additional assay internal standard in the MIRM-ISCC-LC-MS / MS approach. Therefore, the assay performance can be further improved by spiking the SIL analyte as early as possible in the sample preparation, as in the analysis of the small molecule drug Daclatasvir in Example 3, where the sample was spiked with SIL Daclatasvir at the beginning of the sample preparation. However, in the case of protein analysis using immunocapture, the labeled peptide can only be spiked after immunocapture and any variation during immunocapture, and trypsin digestion is not tracked and corrected, as in the analysis of CD73 protein in Example 1. This problem can be solved by spiking the SIL protein with a portion of a labeled surrogate peptide at the beginning of the sample preparation.
[0162] Because ISCCs are present in each individual sample and there is currently no commercially available software that can construct ISCCs using peak areas from multiple MIRM channels, in-house developed software was used in this study to generate ISCCs and calculate sample concentrations in batches using a weighted least squares regression algorithm. Widespread application of the MIRM-ISCC-LC-MS / MS method will depend on commercially available software development by major mass spectrometry companies.
[0163] Example 4 Quantitative LC-MS / MS Bioanalysis Using One-Sample Multipoint External Calibration Curve and Isotopic Sample Dilution with MIRM Technology The LC-MS / MS system used was a triple quadrupole 6500 mass spectrometer (AB Sciex, Foster City, CA) coupled to a Nexera UPLC system (Shimadzu, Columbia, MD). The UPLC system consisted of two LC-30AD pumps, one SIL-30ACMP autosampler, and one CTO-30AS column heater. Separation was performed on an Acquity HSS T3 analytical column (2.1 mmx50 mm, 1.8 μm particle size) (Waters, Milford, MA) by gradient elution with a mobile phase of 10 mM ammonium acetate / water / acetonitrile (90 / 10) containing 0.1% formic acid, and 10 mM ammonium acetate / water / acetonitrile (10 / 90) containing 0.1% formic acid. The flow rate was 0.8 mL / min. LC-MS / MS data were acquired using Analyst Software (1.6.2) (AB Sciex, Foster City, Calif.).
[0164] Sample preparation for LC-MS / MS quantification of daclatasvir using multi-sample external calibration curve, one-sample multi-point external calibration curve, and ISCC. 13 C 2 15 N 4 -All stock solutions for daclatasvir were prepared in acetonitrile / DMSO (1 / 1, v / v). Daclatasvir at 20000ng / mL was prepared by appropriate dilution of the 0.5mg / mL stock solution in human plasma. Multi-sample external calibration curves of daclatasvir at concentrations of 1000, 800, 500, 100, 20, 4, 2, and 1ng / mL were prepared by serial dilution of daclatasvir at 20000ng / mL in human plasma. QC samples at 20000, 5000, 800, 500, 40, 3, and 1ng / mL of daclatasvir were prepared by serial dilution of the 0.5mg / mL stock solution of daclatasvir.
[0165] A concentration of 5000ng / mL of daclatasvir was prepared in methanol / water (10 / 90) by appropriate dilution of a 0.5mg / mL stock solution of daclatasvir, and this solution was used to construct a one-sample multipoint external calibration curve. 13 C 2 15 N 4 -Daclatasvir is 0.5 mg / mL 13 C 2 15 N 4 -A stock solution of daclatasvir was prepared by appropriate dilution with methanol / water (10 / 90) and this solution was used to construct the ISCC in each sample and also as the assay stable isotope-labeled internal standard (SIL-IS) for both the multi-sample external calibration curve and the one-sample multi-point external calibration curve approach.
[0166] Aliquots of 100 μL of plasma samples were transferred to a 96-well plate for two multi-sample external calibration curves at 1-1000 ng / mL, six replicates of QC samples at 1, 3, 40, 500, and 800 ng / mL, and two one-sample multi-point external calibration curves (two blank plasma samples spiked with known amounts of daclatasvir). QC samples at 5000 and 20000 ng / mL were diluted 100 and 200 times, respectively, and 100 μL of both diluted and undiluted QC samples at 5000 and 20000 ng / mL (six replicates each) were transferred to a 96-well plate. A volume of 20 μL of daclatasvir at 5000 ng / mL in 10% methanol and 90% water was added to two blank human plasma samples to construct two one-sample multipoint external calibration curves, and a volume of 20 μL of 10% methanol and 90% water was added to the other sample as offset. 13 C 2 15 N 4 -A 20μL aliquot of daclatasvir was added to each plasma sample in the 96-well plate. For the multi-sample external calibration curve and the one-sample multipoint external calibration curve,13 C 2 15 N 4 -Daclatasvir was used as the assay SIL-IS and was also used as the SIL analyte to construct the ISCC for each sample.
[0167] Samples were extracted by liquid-liquid extraction (H. Jiang et al, Journal of Chromatography A 2012, 1245, 117-121) using a Janus Mini liquid handler (PerkinElmer, Waltham, MA). A volume of 50 μL of 1 M ammonium bicarbonate buffer was added to each sample, followed by 600 μL of MTBE. The 96-well plate was vortexed for 5 min, and 400 μL of the supernatant was transferred to a new 96-well plate and evaporated to dryness at 50 °C. For LC-MS / MS analysis, samples were reconstituted with 100 μL of 10% methanol / water.
[0168] An overview of the MRM and MIRM transitions tracked for each of the multi-sample external calibration curves, one-sample multipoint external calibration curves (OSMECC), and within-sample calibration curves (ISCC) is shown in Figure 4A. The SRM channels used for isotopic sample dilution and the corresponding isotope dilution factors (IDFs) are also shown in Figure 4A. Calibration curve performance for the two multi-sample external calibration curves and the two one-sample multipoint external calibration curves used, as well as the two ISCCs, are shown in Figure 4B.
[0169] Accuracy and precision data for QC samples using multi-sample external calibration curves, one-sample multi-point external calibration curves, and ISCC are shown in Figure 5A. The 5000 and 20000ng / mL QC samples were physically diluted 100-fold and 200-fold by two-step dilution, respectively. In this example, the concentrations of the same set of QC samples were calculated by three different types of calibration curves. Accurate measurement of QC samples was demonstrated at all concentration levels by these three types of calibration curves, demonstrating that both the one-sample multi-point calibration curve and ISCC can provide bioanalytical data with similar accuracy to the traditional multi-sample external calibration curve. Therefore, they can be used in LC-MS / MS bioanalytical assays where multi-sample external calibration curves are traditionally used.
[0170] To eliminate the sample dilution step for samples with concentrations above the ULOQ of the assay, the isotope sample dilution approach using MIRM technology was evaluated with all three types of calibration curves using QC samples of 5000, 20000, and 50000 ng / mL. As shown in Figure 5B, accurate measurements of QC samples at 5000 and 20000 ng / mL were achieved using three different calibration curves with isotope dilution factors (IDFs) up to 1040-fold. Only ISCC provided accurate measurements of QC samples at 20000 ng / mL with IDFs of 1695 and 4386. Furthermore, IDFs of 1695 and 4386 were evaluated for ISCC using QC samples with a concentration of 50000 ng / mL, and accurate measurements were achieved for both IDFs. Therefore, the isotope sample dilution approach can be used in LC-MS / MS bioanalytical approaches to eliminate the physical sample dilution step. ***
[0171] Throughout this application, various publications are referenced in parentheses by author name and date, or by patent or patent publication number. The disclosures of these publications are incorporated herein by reference in their entireties in order to more fully describe the state of the art known to those skilled in the art as of the date of disclosure described and claimed herein. However, citation of a reference herein should not be construed as an admission that such reference is prior art to the present disclosure.
Claims
1. A method for quantifying the concentration of at least one analyte in a sample, comprising spiking a sample containing at least one analyte with one or more known amounts of stable isotope labeled (SIL) analytes and constructing one or more intra-sample calibration curves (ISCCs) by multiple isotopic species reaction monitoring (MIRM) of each spiked SIL analyte, wherein MIRM of a SIL analyte refers to multiple reaction monitoring of multiple isotopic transitions of a SIL analyte; the ISCC of each analyte is calculated by combining the theoretical isotope abundance (analyte concentration equivalent) calculated at the MIRM transition with the corresponding isotope abundance measured by tandem mass spectrometry (MS / MS) at the MIRM transition. a concentration of at least one analyte in the sample is quantified using the established ISCC and the measured peak areas for the analyte from a liquid chromatography-tandem mass spectrometry (LC-MS / MS) step; the tandem mass spectrometer is operated in a multiple reaction monitoring mode, and the theoretical isotopic abundances for each MIRM transition (m / z) of the SIL analyte and the naturally occurring isotopic species of the SIL analyte from (p+Zp+α) / Zp to (d+Zd+β) / Zd are calculated according to the formula (I): Isotope abundance in the MIRM transition of (p+Zp+α) / Zp→(d+Zd+β) / Zd= [Relative isotopic distribution of daughter ions at mass (d+Z d +β)]* [Relative isotopic distribution of neutral losses in the mass of n+(α-β)] (I) [In the formula, m / z is the mass-to-charge ratio p is the monoisotopic mass of the parent molecule of the SIL analyte Z p is the charge number of the parent ion d is the monoisotopic mass of the daughter fragment of the SIL analyte Z d is the charge number of the daughter ion n is the monoisotopic mass of the neutral loss of the SIL analyte p = d + n α and β are integers that are the number of additional neutrons in the parent ion and daughter ion, respectively, where α>0, β>0, and α>β. Z p and Z d are integers. A method calculated based on the above.
2. (i) the analyte, the SIL analyte, and naturally occurring isotopic species of the SIL analyte are ionized in a mass spectrometer to produce protonated (or deprotonated) parent ions of the analyte, the SIL analyte, and naturally occurring isotopic species of the SIL analyte; (ii) in the mass spectrometer, the parent ion of the analyte, the parent ion of the SIL analyte, and the parent ion of a naturally occurring isotopic species of the SIL analyte are fragmented at the same cleavage site to give rise to neutral loss and daughter ions; (iii) monitoring the transition of the analyte from a parent ion to a daughter ion in a mass spectrometer; (iv) measuring the peak area for the transition from parent ion to daughter ion of the analyte; (v) monitoring selected multiple transitions from parent ions of the SIL analyte and parent ions of naturally occurring isotopic species of the SIL analyte to daughter ions of the SIL analyte and daughter ions of naturally occurring isotopic species of the SIL analyte in a mass spectrometer ("multiple isotopic species reaction monitoring" or "MIRM"); (vi) measuring the peak area of each MIRM transition, wherein the MIRM transitions include selected transitions from a parent ion of the SIL analyte and a parent ion of a naturally occurring isotopic species of the SIL analyte to a daughter ion of the SIL analyte and a daughter ion of a naturally occurring isotopic species of the SIL analyte; The method of claim 1.
3. The maximum analyte concentration equivalent (ISCC "upper limit of quantitation" or "ULOQ") is calculated using the formula (II): (M / V)*(M 分析物 / M SIL分析物 )ng / mL (II) [In the formula, M (ng) is the total amount of SIL analyte added to the sample; V is the sample volume (mL) before addition of the SIL analyte; M 分析物 is the molecular weight of the analyte; M SIL分析物 is the molecular weight of the SIL analyte. The method of claim 1 , wherein the calculation is based on
4. The one or more other analyte concentration equivalents in the MIRM transition are represented by formula (III): I a *ULOQ (ng / mL) (III) [In the formula, I a is the calculated theoretical isotopic abundance of the MIRM transition of the SIL analyte or a naturally occurring isotopic species of the SIL analyte. The method according to claim 3, wherein the calculation is based on
5. The method of any one of claims 1 to 4, wherein the analyte is a protein or a peptide.
6. The method of any one of claims 1 to 5, wherein the SIL analyte is a stable isotope labeled protein or peptide.
7. 7. The method of claim 6, wherein the parent ion of the SIL analyte comprises at least 3 amino acids, at least 4 amino acids, at least 5 amino acids, at least 6 amino acids, at least 7 amino acids, at least 8 amino acids, at least 9 amino acids, at least 10 amino acids, at least 11 amino acids, at least 12 amino acids, at least 13 amino acids, at least 14 amino acids, at least 15 amino acids, at least 16 amino acids, at least 17 amino acids, at least 18 amino acids, at least 19 amino acids, or at least 20 amino acids.
8. 8. The method of claim 6 or 7, wherein the parent ion of the SIL analyte comprises an amino acid sequence of 4-20 amino acids, 4-15 amino acids, 5-15 amino acids, 4-14 amino acids, 5-14 amino acids, 5-13 amino acids, 5-12 amino acids, 6-15 amino acids, 6-14 amino acids, 6-13 amino acids, 6-12 amino acids, 6-11 amino acids, 6-10 amino acids, 6-9 amino acids, 6-8 amino acids, 7-15 amino acids, 7-14 amino acids, 7-13 amino acids, 7-12 amino acids, 7-11 amino acids, 7-10 amino acids, or 7-9 amino acids.
9. The method of any one of claims 1 to 8, wherein the analyte is an antibody.
10. The method of any one of claims 1 to 8, wherein the analyte is a fusion protein.
11. 9. The method of any one of claims 1 to 8, wherein the analyte is PD-1, PD-L1, CD73, an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CD73 antibody, or any combination thereof.
12. The method of any one of claims 1 to 8, wherein the analyte is a small molecule.
13. 13. The method of claim 12, wherein the small molecule has a molar mass of at least 100 g / mol, at least 200 g / mol, at least 300 g / mol, at least 400 g / mol, at least 500 g / mol, at least 600 g / mol, at least 700 g / mol, at least 800 g / mol, at least 900 g / mol, at least 1000 g / mol, at least 1100 g / mol, at least 1200 g / mol, at least 1300 g / mol, at least 1400 g / mol, at least 1500 g / mol, at least 1600 g / mol, at least 1700 g / mol, at least 1800 g / mol, at least 1900 g / mol, or at least 2000 g / mol.
14. 14. The method of any one of claims 1 to 13, wherein the SIL analyte comprises at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 stable isotope labels.
15. The SIL analyte is selected from the group consisting of 3-20 isotopic labels, 3-19 isotopic labels, 3-15 isotopic labels, 3-10 isotopic labels, 3-8 isotopic labels, 3-7 isotopic labels, 3-6 isotopic labels, 4-15 isotopic labels, 4-10 isotopic labels, 4-8 isotopic labels, 4-7 isotopic labels, 4-6 isotopic labels, 5-8 isotopic labels, 15. The method of claim 14, comprising: 5 to 7 isotopic labels, 6 to 10 isotopic labels, 6 to 8 isotopic labels, 7 to 16 isotopic labels, 8 to 16 isotopic labels, 8 to 15 isotopic labels, 9 to 15 isotopic labels, 9 to 14 isotopic labels, 10 to 14 isotopic labels, 10 to 13 isotopic labels, or 11 to 13 isotopic labels.
16. 16. The method of any one of claims 2 to 15, wherein each measured relative peak area at a MIRM transition has a deviation of less than 15% from the calculated theoretical isotopic abundance at the corresponding MIRM transition of the SIL analyte or a naturally occurring isotopic species of the SIL analyte.
17. 17. The method of claim 16, wherein at least one relative peak area measured at a MIRM transition has a deviation of less than 14%, less than 13%, less than 12%, less than 11%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.1%, less than 0.01%, less than 0.001%, or less than 0.0001% from the theoretical isotopic abundance calculated at the corresponding MIRM transition of the SIL analyte or a naturally occurring isotopic species of the SIL analyte.
18. 18. The method of claim 17, wherein at least one of the relative peak areas measured at the MIRM transitions has a deviation of between 1% and 15% of the theoretical isotopic abundance calculated at the corresponding transition of the SIL analyte or a naturally occurring isotopic species of the SIL analyte.
19. 20. The method of claim 18, wherein the number of MIRM transitions is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20.
20. 20. The method of claim 19, wherein the number of MIRM transitions is between 2 and 20.
21. 21. The method of any one of claims 2 to 20, wherein the analyte concentration equivalents of the maximum MIRM and the minimum MIRM differ by at least 10, at least 100, at least 200, at least 300, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1100, at least 1200, at least 1300, at least 1400, at least 1500, at least 1600, at least 1700, at least 1800, at least 1900, or at least 2000 fold.
22. 22. The method of any one of claims 1 to 21, wherein the calculated theoretical isotopic abundances of two selected MIRM transitions are at least 0.01%, at least 0.05%, at least 0.1%, at least 0.5%, at least 1%, at least 1.5%, at least 2%, at least 2.5%, at least 3%, at least 3.5%, at least 4%, at least 4.5%, at least 5%, at least 5.5%, at least 6%, at least 6.5%, at least 7%, at least 7.5%, at least 8%, at least 8.5%, at least 9%, at least 9.5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% apart.
23. 23. The method of any one of claims 1-22, wherein the SIL analyte comprises less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, or less than 0.1% unlabeled analyte.
24. The sign 2 H. 13 C. 15 N. 33 S. 34 S. 36 S. 17 O, or 18 The method according to any one of claims 1 to 23, wherein O is O.
25. 25. The method of any one of claims 1 to 24, wherein one or more of the protonated or deprotonated molecular ions are singly, doubly, triply or more charged.
26. The method of any one of claims 1 to 25, wherein the mass spectrometer is a triple quadrupole mass spectrometer comprising Q1, Q2, and Q3.
27. 27. The method of claim 26, wherein the resolution used for Q1 and Q3 is unit resolution.
28. 27. The method of claim 26, wherein the resolutions used for Q1 and Q3 are different.
29. 27. The method of claim 26, wherein the resolution used for Q1 is higher than the unit resolution of Q3.
30. The method according to any one of claims 1 to 29, wherein an intra-sample calibration curve (ISCC) composition is added before or during sample preparation.
31. The method of any one of claims 1 to 30, wherein the method reduces the overall runtime of an instrument.
32. The method according to any one of claims 1 to 31, wherein no external calibration curve is used.
33. The method of any one of claims 1 to 32, wherein the analyte is a biomarker.
34. The method of any one of claims 1 to 32, wherein the analyte is a metabolite.
35. 33. The method of any one of claims 1 to 32, wherein the sample is serum, tissue, biopsy tissue, formalin fixed / paraffin embedded (FFPE), plasma, saliva, cerebrospinal fluid, tears, urine, synovial fluid, dried blood spot, or any combination thereof.
36. The method of any one of claims 1 to 8 and 14 to 35, wherein the analyte is CD73 or a part thereof.
37. The SIL analyte is V[Ile( 13 C 6 , 15 37. The method of claim 36, wherein the SIL peptide is YPAVEGR (SEQ ID NO: 1).
38. The method of any one of claims 1 to 8 and 14 to 35, wherein the analyte is PD-1 or a portion thereof.
39. The SIL analyte was LAAFPED[Arg( 13 C 6 , 15 N 4 40. The method of claim 38, wherein the SIL peptide is SEQ ID NO:
2.
40. The method of any one of claims 1 to 8 and 14 to 35, wherein the analyte is PD-L1 or a portion thereof.
41. The SIL analyte was LQDAG[Val( 13 C 5 , 15 41. The method of claim 40, wherein the peptide is:
42. 36. The method of any one of claims 1-8 and 14-35, wherein the analyte is daclatasvir.
43. SIL analytes 13 C 2 15 N 4 The method of claim 42, wherein said compound is daclatasvir.
44. 1. A quantitative LC-MS / MS bioanalysis method using one-sample multi-point external calibration curves, comprising spiking one or more known quantities of one or more analytes into a blank matrix sample to generate one or more single-sample multi-point external calibration curves (OSMECC) by multiple isotopic species reaction monitoring (MIRM) of each spiked analyte, where MIRM of an analyte means multiple reaction monitoring of multiple isotopic transitions of the analyte; OSMECC of each analyte is the calculated theoretical isotopic abundance (analyte concentration equivalent) at the MIRM transition and the measured tandem mass spectrometry (MS / MS) peak area (or assay area) at the corresponding MIRM transition. a peak area ratio (peak area ratio if an internal standard is used in the assay) is established in the blank matrix sample; the concentration of at least one analyte in the study sample is quantified using the peak area (or peak area ratio if an internal standard is used in the assay) measured for the analyte in the study sample from the OSMECC established in the blank matrix sample and a liquid chromatography-tandem mass spectrometry (LC-MS / MS) step; the peak area ratio of the analyte is the peak area of the analyte divided by the peak area of the internal standard; the tandem mass spectrometer is operated in a multiple reaction monitoring mode, and the theoretical isotopic abundance ratio for each MIRM transition (m / z) of the analyte and the analyte's naturally occurring isotopic species (p+Zp+α) / Zp to (d+Zd+β) / Zd is calculated according to the formula (I): Isotope abundance in the MIRM transition of (p+Zp+α) / Zp→(d+Zd+β) / Zd= [Relative isotopic distribution of daughter ions at mass (d+Z d +β)]* [Relative isotopic distribution of neutral losses in the mass of n+(α-β)] (I) [In the formula, m / z is the mass-to-charge ratio p is the monoisotopic mass of the parent molecule of the analyte Z p is the charge number of the parent ion d is the monoisotopic mass of the daughter fragment of the analyte Z d is the charge number of the daughter ion n is the monoisotopic mass of the neutral loss of the analyte p = d + n α and β are integers that are the number of additional neutrons in the parent ion and daughter ion, respectively, where α>0, β>0, and α>β. Z p and Z d are integers. A method calculated based on the above.
45. The maximum analyte concentration equivalent (OSMECC "upper limit of quantitation" or "ULOQ") is calculated according to formula (IV): (M / V)*ng / mL (IV) [In the formula, M (ng) is the total amount of analyte added to the sample; V is the sample volume (mL) before addition of analyte. The method of claim 44, wherein the calculation is based on
46. The one or more other analyte concentration equivalents in the MIRM transition are represented by formula (III): I a *ULOQ (ng / mL) (III) [In the formula, I a is the calculated theoretical isotopic abundance of the MIRM transition of the analyte or a naturally occurring isotopic species of the analyte. The method of claim 45, wherein the calculation is based on
47. The method of any one of claims 44 to 46, wherein the analyte is a protein or peptide.
48. 48. The method of claim 47, wherein the parent ion of the analyte comprises at least 3 amino acids, at least 4 amino acids, at least 5 amino acids, at least 6 amino acids, at least 7 amino acids, at least 8 amino acids, at least 9 amino acids, at least 10 amino acids, at least 11 amino acids, at least 12 amino acids, at least 13 amino acids, at least 14 amino acids, at least 15 amino acids, at least 16 amino acids, at least 17 amino acids, at least 18 amino acids, at least 19 amino acids, or at least 20 amino acids.
49. 49. The method of claim 47 or 48, wherein the parent ion of the analyte comprises an amino acid sequence of 4-20 amino acids, 4-15 amino acids, 5-15 amino acids, 4-14 amino acids, 5-14 amino acids, 5-13 amino acids, 5-12 amino acids, 6-15 amino acids, 6-14 amino acids, 6-13 amino acids, 6-12 amino acids, 6-11 amino acids, 6-10 amino acids, 6-9 amino acids, 6-8 amino acids, 7-15 amino acids, 7-14 amino acids, 7-13 amino acids, 7-12 amino acids, 7-11 amino acids, 7-10 amino acids, or 7-9 amino acids.
50. The method of any one of claims 44 to 49, wherein the analyte is an antibody.
51. The method of any one of claims 44 to 49, wherein the analyte is a fusion protein.
52. 50. The method of any one of claims 44-49, wherein the analyte is PD-1, PD-L1, CD73, an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CD73 antibody, or any combination thereof.
53. The method of any one of claims 44 to 46, wherein the analyte is a small molecule.
54. 54. The method of claim 53, wherein the small molecule has a molar mass of at least 100 g / mol, at least 200 g / mol, at least 300 g / mol, at least 400 g / mol, at least 500 g / mol, at least 600 g / mol, at least 700 g / mol, at least 800 g / mol, at least 900 g / mol, at least 1000 g / mol, at least 1100 g / mol, at least 1200 g / mol, at least 1300 g / mol, at least 1400 g / mol, at least 1500 g / mol, at least 1600 g / mol, at least 1700 g / mol, at least 1800 g / mol, at least 1900 g / mol, or at least 2000 g / mol.
55. 55. The method of any one of claims 44 to 54, wherein the number of MIRM transitions is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20.
56. 56. The method of claim 55, wherein the number of MIRM transitions is between 2 and 20.
57. 57. The method of any one of claims 44-56, wherein the analyte concentration equivalents of the maximum MIRM and the minimum MIRM differ by at least 10, at least 100, at least 200, at least 300, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1100, at least 1200, at least 1300, at least 1400, at least 1500, at least 1600, at least 1700, at least 1800, at least 1900, or at least 2000 fold.
58. 58. The method of any one of claims 44 to 57, wherein the calculated theoretical isotopic abundances of two selected MIRM transitions are at least 0.01%, at least 0.05%, at least 0.1%, at least 0.5%, at least 1%, at least 1.5%, at least 2%, at least 2.5%, at least 3%, at least 3.5%, at least 4%, at least 4.5%, at least 5%, at least 5.5%, at least 6%, at least 6.5%, at least 7%, at least 7.5%, at least 8%, at least 8.5%, at least 9%, at least 9.5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% apart.
Citation Information
Patent Citations
Method for detecting mass change in mass spectrometry method and method for quantifying absolute amount of stable isotope-labeled protein
WO2012111249A1
